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Abstract 
Immunotherapy is a valuable approach to target tumour cells by stimulating the body’s 
adaptive immune system. To achieve this objective, it is important to identify and study 
antigens that are distinctively expressed in cancer and can be used effectively to initiate or 
enhance immune responses. 
T21 (Testis clone 21) was identified as a member of cancer/testis antigen (CTAs) family of 
proteins using a modified SEREX technique and can be considered a promising prostate-
associated tumour antigen, shown to elicit a humoral immune response in prostate cancer 
patients. T21 has also been shown to be over-expressed in malignant glands of the prostate 
compared to benign glands and stroma at the mRNA level. Since T21 shares significant 
similarity with the Centrosomal Protein, CEP290, which has been implicated in several cilia 
associated syndromic disorders such as Joubert syndrome, it was necessary to determine 
similarities and differences in the expression and functionality of these two molecules to 
facilitate further studies on the role of T21 in prostate cancer tumourigenesis. 
As with the majority of identified cancer/testis antigens, the role of T21 in cancer remains 
undetermined. Therefore, investigations were initiated to understand the potential function of 
T21 in cancer cells. Next Generation Sequencing (NGS) data have been previously obtained 
following T21 knockdown/silencing in PC3 cells and the expression profiling of this data 
indicated that T21 function was related to several pathways involved in tumourigenesis. 
Genes that were either up or down regulated in the presence of T21 were validated by qRT-
PCR and the results provided evidence that T21 may share functional activity these various 
genes and be implicated as a key driver of important signaling pathways. 
 
The up or down regulation of molecules associated with key signaling pathways was 
established from the NGS data and validated by qRT-PCR. The effect of T21 silencing on the 
associated MAPK pathways was further investigated by using proteome profiler arrays. The 
results indicated the potential role that T21 may play in cancer cell growth regulation and 
suggested that T21 is potentially a central player in the cancer process. Finally, the data 
presented here strongly supports the hypothesis of T21 having a significant role in the 
biology of malignant cells. This, together with its potential use in immunotherapy, that 
warrants further investigation. 
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CHAPTER I 
INTRODUCTION  
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1 CHAPTER ONE: Introduction 
1.1 Cancer 
1.1.1  Cancer overview  
Cancer has remained as one of the biggest challenges in the biological and medical fields 
which have continuously attracting people’s attention, especially scientists and medical 
professionals. The recent global data provided by World Health Organisation (WHO) (on line 
at http://www.who.int/cancer/en/) shows that the cancer is considered to be the leading cause 
of morbidity and mortality worldwide and as the second most lethal diseases following the 
cardiovascular diseases. The cancer incidence relates mainly to lifestyle behaviours and 
increases in aging populations significantly in most developed countries such as UK and the 
USA. Globally, there were 12.7 million new cancer cases diagnosed in 2008 and 
approximately 7.6 million cancer-related deaths. In 2011, there were 331,487 people in the 
UK diagnosed with breast, lung, prostate and bowel cancers accounting around 54% of the 
new cases. In the UK population, there is a one in three lifetime risk of cancer with lung, 
prostate, breast and colorectal cancers as the leading causes. Furthermore, in 2012, a total of 
161,823 deaths of cancer were reported. (Cancer Research U.K).  
Cancer, in medical diagnosis, is categorised as benign or malignant, based on the cancer 
behaviour in terms of spreading and metastasising.  Benign cancers (non-malignant) are 
considered non-invading tumours to other parts except the origin tissue. However, they might 
exist as a complex, or continuously growing large mass that can cause damage to surrounding 
tissues or organs. In contrast, malignant tumours are represented as metastatic cancers that 
can spread to other parts of the body. The majority of cancers (around 85%) occurs within the 
epithelial cells and is classified as Carcinomas (Cancer Research U.K). Adenocarcinomas, on 
the other hand, are originated from glandular tissues (e.g. in breast) and Sarcomas are derived 
from mesoderm cells that exist in organs such as bones and muscles. 
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1.1.2  Prostate Cancer 
 
Prostate cancer is considered as the most common male non-cutaneous malignancy in the 
United Kingdom (http://www.cancerresearchuk.org/).  The prostate gland anatomically is 
involved within the males’ reproductive and urinary systems as an oval shaped organ with a 
rounded tip. It is approximately 2-3 cm in size and enlarges gradually with age. Its exact 
location is at the bottom of the bladder, surrounding the upper part of the urethra and the 
seminal vesicles where it encourages seminal fluid liquefaction. The prostate gland is 
composed of various types of cells covered in a layer of connective tissue (the prostatic 
capsule). These cells types are: (1) gland cells type that have a role in producing the fluid 
portion of semen; (2) muscle cells that control urine flow and ejaculation; and (3) fibrous 
cells to provide the prostate gland’s supportive structure. The gland structure is surrounded 
by seminal vesicles on both sides to produce semen for the sperm that is carried to them from 
the testicles by the vas deferens. Moreover, there are nerve bundles that have the function of 
controlling the bladder and erection process beside muscles that control urination. 
The function of a prostate is mainly governed by endocrine signalling which has been widely 
noticed in having an important role in prostate cancer progression. The prostate gland, 
structurally, is divided into peripheral, transition and central zones. The peripheral zone is the 
largest part of prostate gland which locates closer to the rectum and, subsequently, it is the 
easiest zone to be examined by physicians during a Digital Rectal Examination (DRE). The 
transition zone location is at the middle area of prostate gland between the peripheral and 
central zones surrounding the urethra. This zone size forms up to 20% of the prostate gland 
and is gradually enlarged in men over 40 years of age. As a result, the transition zone is the 
largest zone in prostate gland where benign prostatic hyperplasia (BPH) is extensively 
observed. 
It has been reported that the majority of prostate cancers originate in the peripheral zone of 
the prostate gland (70-75%), while 15% arises from the central zone and 10-15% occur in 
transitional zone (Bracarda et al., 2005) (Figure 1.1.1). In addition, the significant majority 
(95%) of the prostate cancers are diagnosed as adenocarcinoma that has the ability to spread 
to the surrounding tissues or invade seminal vesicles and the bladder. Therefore, there is a 
considerable potential of metastasis to distant organs such as lymph nodes and bones. 
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Figure 1.1. 1 Prostate zones.  
(adapted from Nature Reviews Cancer 2007) 
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1.2 Current methods of diagnosis 
1.2.1 Diagnosis and screening for prostate cancer 
 
Prostate cancer can often be asymptomatic, however patients may present with lower urinary 
tract symptoms which are also associated with other conditions such as prostatitis and benign 
prostatic hyperplasia (BHP). In addition to this, patients with prostate cancer may also 
present with lower back or pelvic pain as a major indication of metastatic disease. Currently 
there are three diagnostic tools used for detecting prostate cancer when patients present with 
such symptoms. An initial measurement of serum PSA level, Digital Rectal Examination 
(DRE), transrectal ultrasound and biopsy sampling, the results of which are taken together to 
form a diagnosis of disease status and the course of action that should be taken.  
Prostate-specific antigen (PSA) is a 34kDa glycoprotein, a serine protease with 
chymotrypsin-like activity which is produced only in prostatic epithelial cells. From here it is 
secreted into the prostatic ductal system where it proteolyses gel proteins (SEMG1 and 
SEMG2) in order to liquefy seminal fluid. The production of PSA is restricted to the prostate 
epithelium and in healthy males, is largely limited to this area with little outflow into the 
circulatory system. PSA levels found in blood range from <0.1 to 10
4
 ng/ml with levels the 
lower range found in < 50 year old males, a figure that increases slightly with age. Men with 
advanced prostate cancer, whatever their age, have a marked increase in PSA levels found in 
the blood (10
2
 ng/ml). High levels of PSA are also found in normal healthy males and in 
those with other prostate related conditions (prostatitis and BHP) and is influenced by age, 
body mass and racial differences, therefore can not be exclusively associated with prostate 
cancer. PSA levels in the blood are therefore a reflection of its release into the blood and not 
the elevated expression of PSA in the prostate due to presence of cancer. The numerous 
factors that contribute to elevated levels of blood PSA have made it difficult to pin down an 
exact threshold for evidence of prostate cancer and for this reason PSA screening would be 
unsuitable for population screening due to its lack of specificity and sensitivity (Lilja et al., 
2008).  
PSA testing may be advantageous for earlier diagnosis of disease, however the primary 
drawback of PSA testing is the lack of distinction between high risk and low risk prostate 
cancers that would be clinically insignificant and would not result in patient death. 
Importantly, the increasing incidence of newly diagnosed cases of prostate cancer in the UK 
6 
 
has not resulted in a reduced mortality rate bringing into question firstly the true benefit of 
PSA guided diagnosis and secondly its lack of improvement on treatment and disease 
management over the past few decades.    
With this said, assessing for increased levels of PSA in blood can not be used in isolation to 
detect and diagnose prostate cancer but instead used as a preliminary assessment for more 
invasive procedures, namely DRE and biopsy examination which gives more definitive 
evidence of disease. Biopsy cores are used to determine the TNM staging along with a 
Gleason score based on cell morphology and cellular arrangement. Further analysis using 
tissue from core biopsy is performed by assessing specific markers by immunohistochemistry 
staining. A cocktail of markers are used containing basal markers such as high molecular 
weight cytokerins (34βE12, cytokerin 5/6) and nuclear protein p63 (absent in prostate 
adenocarcinoma) and a prostate cancer specific marker such as alpha-methyl-CoA-Racemase 
(AMACR), which is present in 80-100% of prostate cancers. These markers are used to 
determine disease status and in addition distinguish between malignant glands and benign 
lesions. Additional diagnostic procedures may be undertaken if metastatic disease is 
suspected using CT, MRI and bone scans to determine locally advanced or metastatic spread 
to distant organs (Yu et al, 2007; Lin et al, 2012).  
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1.3 Current Treatment 
 
Treatment strategies are devised on criteria derived from stage and spread of disease and 
Gleason grading of disease as well as the age and general health of the patient. As described 
earlier, prostate cancers are slow growing and are often asymptomatic and are not always the 
cause of mortality in many elderly patients who have the disease. The option of unnecessary 
and potentially risky invasive treatment may be avoided by clinicians who opt for watchful 
waiting or active surveillance policy, whereby patients are monitored via PSA levels and core 
biopsies in order to delay invasive treatments and potentially avoid overtreatment of non- 
aggressive forms of prostate cancer.     
Currently, radical prostatectomy in which the prostate gland and areas of surrounding tissue 
are surgically removed is the mainstay of treating localised disease and can be curative. 
Following surgery or as an alternative treatment, external beam radiotherapy (EBRT) and 
brachytherapy (internal radiotherapy) can be used to target and destroy rapidly proliferating 
cancer cells in order to limit spread of disease. In more recent years, further technological 
advancements in the field of radiotherapy, including 3D-conformal radiotherapy and intensity 
modulated radiotherapy, have increased targeting precision.        
Progression beyond the capsule of the gland to the surrounding tissue where there is local or 
further advanced spread requires further treatment using radiotherapy and hormone therapy 
with the addition of chemotherapy as treatment for androgen refractory prostate cancer and 
metastasis of which a significant proportion of patients gradually progress to and currently 
remains incurable. Hormone therapy is then used to reduce androgen levels in order to stem 
androgen-dependant tumour growth and can be approached surgically (bilateral orchiectomy) 
or using combinations of chemical castrators namely competitive binding of the androgen 
receptor using anti-androgens such as Flutamide and Bicalutamide, the use of luteinising 
hormone blockers (LH-RH) and gonadotrophin releasing hormone analogues (Gn-RH 
analogues) used to down regulate the production of androgens in the pituitary. After cancer 
fails to respond to previous hormone therapy intervention, a second line hormone therapy 
may be used such as steroids Prednisolone and Dexamethasone or diethylstilbestrol 
(Stilboestrol), which mimics the female hormone oestrogen which can in turn reduce 
testosterone levels (Malkowicz 2001).  
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Chemotherapy combinations of taxanes (paclitaxel and docetaxel) and prednisone, have been 
shown to increase overall patient survival and in addition have a positive impact on quality of 
life after hormone-refractory prostate cancer (Tannock, 2004 and Haas et al., 2001). Existing 
hormone therapies are partially effective in limiting the progression of disease, however the 
majority of patients relapse to an androgen resistant form of disease and have limited in 
further treatment options, thus increasing evidence suggests that better tumour targeting 
strategies are required.  
In recent years, there has been an emergence of a number of therapeutic approaches to 
hormone refractory prostate cancer, all with varying degrees of success. Treatments such as 
FDA approved taxane cabazitaxel, a semi-synthetic taxane which has proven to reduce 
susceptibility to taxane resistant prostate cancer, in addition to increasing the effective impact 
on metastatic lesions in the brain (de Bono et al., 2010). Another anti-androgen antagonist 
drug, MDV-3100 which is effective in Bicalutamide resistant prostate cancer, blocks 
testosterone binding to the androgen receptor, obstructs movement of androgen receptor to 
the cell nucleus and inhibits DNA binding (Swayers et al., 2009). Targeting androgen 
synthesis using small-molecule inhibitors to enzymes such as CYP17 (such as Abiraterone) 
has been utilised for its anti-tumour activity (de Bono et al., 2008).  On the other hand, the 
long established radiation-based therapy has recently been further advancement using alpha 
radiation instead of gamma and beta radiation. Alpharadin (radium-223 chloride) targets and 
destroys tumour cells and has been shown to more effectively target bone metastases than 
other radiation treatments (Wissing, 2013).   
Research into effective treatment of cancer has turned to the body’s own immune system to 
identify and destroy tumour cells, in particular, circulating tumour cells. This concept of 
instructing the immune system to specifically target tumour cells to avoid more invasive 
treatments which carry a high mortality risk and unwelcome side effects poses an attractive 
approach with recent evidence showing strong potential for successful outcomes. One such 
treatment, called Sipuleucel-T, is an autologous cellular immunotherapy consisting of 
PBMC’s cultured with a recombinant fusion protein PA2024 Prostate Associated Protein 
(PAP) linked to granulocyte-macrophage colony-stimulating factor (GM-CSF) to initiate an 
immune response to tumour cells exhibiting PAP antigens with the overall survival of 
patients on Sipuleucel-T being 4.1 months longer compared to the control patient cohort who 
received conventional treatments (Fishman et al., 2011). Recently, three epitopes of PAP 
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(PAP-114-128) were addressed as a highly relevant peptides that can be used for developing 
vaccine and to be applied in prostate cancer immunotherapy (Saif et al, 2014).  
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1.4 Tumourigensis of cancer 
 
Cancer, as described previously, is a group of diseases with unregulated cell growth and 
division due to acquired accumulations of genetic mutations. These mutations lead to loss of 
the regular control system of the cellular homeostasis (the systems of controlling and 
maintaining the environmental balance in cells) causing dysregulation and imbalanc in the 
cellular differentiation and proliferation (Bertram, 2001). Normal cells are composed of 
complex molecular networks which respond to any instructional signaling from other cells in 
order to control their proliferation, differentiation and programmed cell death (apoptosis). 
These signalling commands are to ascertain the controlled preservation of organ size, 
function and tissue architecture constantly with the body’s requirements. Any disruption of 
these signaling pathways due to genetic mutations may lead to an increase in cell 
proliferation, overtaking inhibitory growth signals and unregulated apoptosis. Furthermore, 
these transformed cells gain the ability to divide and grow indefinitely without restricted 
growth control. These unregulated cells accumulate further genetic mutations which give 
them cell selective growth feature over normal cells and invade (metastasise) to nearby 
tissues, blood and even to the lymph nodes and subsequently form further masses at distant 
organs. Any disruption that might occur to the cellular homeostasis process will noticeably 
destroy the systematic balance of the cell. Meanwhile, the tumour formation will begin to use 
the cellular defining features to be self-sufficiency in terms of growth and inhibitory signal 
insensitivity, an infinite capacity for self-renewal, a resistance to apoptosis, sustained 
angiogenesis and invasion of tissue and metastasis. Hanahan & Weinberg (2011) illustrated 
the hallmarks characteristic of cancer and demonstrating the capability of tumours to 
reprogramme their cellular activities. Cancer cells have the ability to acquire the functionality 
of cell metabolic pathways, promote genomic stress and diversity, escape immune destruction 
and promote inflammation.  
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Figure 1.4. 1 The hallmarks of cancer.  
(Adapted from Hanahan & Weinberg, 2011). 
 
DNA damaging due to carcinogetic materials or exposure to any external environmental is a 
frequent occurrence (Fortini et al., 2003; Lodish et al., 2004), leading to accumulated genetic 
mutations overtime and an increase in the possibility of cancer development. Advancing age 
has also been reported to increase the incidence of various forms of cancer. The influence of 
genetic and epigenetic factors can be classified as following: 
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Environmental carcinogenic factors: 
Both chemical and physical causative agents lead to genes mutations which may initiate cell 
transformation. Chemical carcinogens, for instance, are mostly related to industrial sources 
linked with occupational cancers such as lung cancer and skin malignancies. Smoking 
cigarettes is a cause of lung cancer due to the carcinogenic elements such as benzo-pyrene 
and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (Shopland, 1995; Hecht, 1999). 
DNA structure can be affected, on the other hand, as a result of radiation through prolonged 
exposure to ionising radiation such as ultra-violet radiation (UV) (Pfeifer et al., 2005; 
Belpomme et al., 2007). 
Infectious viral pathogenic factors:  
Many viruses are known to cause cancer. During the infection cycle, the viral genome is 
integrated into the host cell genome transferring malignant characteristics to the human 
genome (Butel, 2000; Carillo-Infante et al., 2007).  The viral oncogenes are effective agents 
inducing neoplasia (Parkin, 2006). For example, cervical cancer is caused as result of Human 
Papilloma Virus (HPV) infection and strongly associated with the development of head and 
neck carcinoma (Schiffman et al., 2007; Lajer and von Buchwald, 2010). HPV carries E6 and 
E7 genes that bind to host cell p53 and retinoblastoma (Rb) proteins, increasing proliferation 
signals that preventing apoptotic cell death. This effect is similar to Hepatitis C Virus (HCV) 
core protein, which causes hepatocellular carcinoma (HCC) (Hassan et al., 2009; Ghittoni et 
al., 2010; Tsai and Chung, 2010). It has also been shown that bacteria (such as helicobacter 
pylori) also have a strong association with cancer due to their role in causing chronic 
inflammation (Eslick et al., 1999).  
Epigenetic factors: 
Carcinogens and viruses directly impact on cell transformation, however, there are also 
abnormal processes which have a modifying role on cell behaviour leading to cancer 
development (Cui et al., 2002). The DNA demethylation/methylation status influences gene 
expression. Numerous human gene promoter regions contain CpG islands which may lead to 
demethylation/methylation spontaneously. This can lead to the expression of genes that 
promote malignant behaviour or inhibit the action of those that act to inhibit transformation 
respectively (Esteller et al., 2001; Ehrlich, 2002; Eden et al., 2006).  
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Epigenetically altered gene expression can be restored, unlike genetic changes, and in some 
instances can be used for diagnostic and prognostic applications. Reversing inversed 
methylation patterns in leukaemias and lymphoma using 5-azacytidine and 5-aza-2’-
deoxycytidine (Kantarjian et al., 2006) has been shown, and similarly in Food and Drug 
Administration (FDA) approved histone deacetylase inhibitors, Vorinostat and Romidepsin in 
cutaneous T cell lymphoma (CTCL) and acute myloid leukemia (AML) (Marks & Breslow, 
2007). 
The failure of DNA repair pathways to repair genomic damage is important and will lead to 
the development of cancer over time through a multistage transformation process (Duesberg 
and Li, 2003). Primary mutants, such as dominant oncogenes, are passed onto the daughter 
cells (Bertram, 2001) and all tumour masses develop as a multistep process following 
unrepaired primary cell mutations (Greenman et al., 2007; Stratton et al., 2009). Moreover, 
carriers of germline mutations are at a greater risk of developing cancer, for example, the 
irregular BRCA gene is the most known germline event related to various types of cancer 
including breast, ovarian, prostate, stomach, pancreas, and colon cancers (Hall et al., 1990; 
Friedenson, 2005).  
The genetic abnormalities which are involved in the process of carcinogenesis occur due to 
the accumulation of mutations in particular two classes of genes that play significant roles in 
cellular pathways that control cellular proliferation and differentiation: proto-oncogenes and 
tumour suppressor genes. Proto-oncogenes are normal genes essential to the control of 
growth and are linked to programmed cell death (apoptosis) which, if mutated, produces 
excessive cellular proliferation. Tumour suppressor genes are key “protector genes” which 
operate to inhibit mitosis and promote cellular destruction in case of DNA damage and 
therefore provide crucial stop signals to ensure correct regulation of cell function and growth. 
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Figure 1.4. 2 The cancer pathways.  
An overview showed the progression from normal cells to tumour state. 
 (Adapted from Bertram, 2000) 
 
The cell reaches to the stage of demonstrating the considered hallmarks of cancer when there 
are mutations in at least five genes. Each gene mutation must enhance the cells capability to 
be adapted and can grow in the host organism; as has been shown in modelled colorectal 
carcinoma development (Fearon & Vogelstein, 1990). Subsequently, the solid tumours have 
been extensively investigated in order to determine the early events that are involved that can 
lead to cancer progression. In prostate cancer, for instance, the Nkx3.1 homeobox gene down 
regulation, appears as a result of promoter methylation (Asatiani et al., 2005), is an early 
initiation event which represents roles in responses to oxidative stress and DNA damage 
(Ouyang et al., 2005; Bowen & Gelmann, 2010). 
The MYC oncogene somatic amplification is also associated and contributed in the early 
onset of the prostate cancer beside TMPRSS2-ERG fusions causing chromosomal 
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rearrangement of 21q resulting in a truncated ERG protein driven by androgen-responsive 
promotor elements of TMPRSS2 (Tomlins et al., 2005). The cell cycle reduction associated 
PTEN tumour suppression in prostate cancer has been shown to precede the gradual 
progression to an androgen independent phenotype (Mulholland et al., 2006). Finally, the 
histone-lysine N-methyltransferase is up regulated and encoded by EZH2 gene as a result of 
of miR-101 frequently  associated to the late stage of metastasis and promoted cellular 
pathways such as RAS and NF-kappaB which are deregulated in various forms of cancer 
(Chiaradonna et al., 2008; Sun & Xiao, 2003) (Figure 1.4.3). The prostate cancer 
development is predominantly slow and shown as asymptomatic disease. When the 
symptoms of the disease are observed, this means the cancer usually has been at advanced 
stage and can metastasis to distant organs such as bones, colon, lymph nodes and brain.  
 
 
 
 
Figure 1.4. 3 Prostate cancer multi-step progression. 
 (Adapted from Abate-Shen & Shen, 2000).  
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1.4.1 Oncogenes 
 
Oncogenes are a class of genes that play a role in stimulating the cell growth and originate 
from modified normal genes called proto-oncogenes and if mutated, can lead to controlled 
cell proliferation. However, a single oncogene requires another mutated gene (viral or 
cellular) through several mechanisms including point mutations, gene amplifications and 
chromosomal translocations to be dominant for causing malignant tumour. The introduction 
of a viral oncogene can be dominant and altered self-genes (proto-oncogenes). An example of 
a viral oncogenes that can lead to and cause cancer is the Sarcoma or Src oncogene induced 
by Rous retrovirus (Martin, 1970; Martin, 2004). There are several additional genetic 
alterations that are important in cancer such as fusion gene production arising by 
translocation (e.g. bcr-abl in CML) and gene amplification.   
Oncogenes can be divided into four subgroups dependent on the where their protein product 
acts. The first two are growth factors and growth factor receptors, for example platelet derived 
growth factor, PDGF, which has a role in initiation of wound healing, but in cancer the PDGF 
BB isoform over-expression results in enhanced signalling for cell division (Barnhill et al., 
1996). The amplification of growth factor receptor genes such as ERB-B2 has a similar 
outcome where the ERB/Her pathways are continually stimulated in some breast cancers. 
Oncogenic activation of signal transduction pathways such as genes encoding for the Ras 
family genes produce proteins and protein regulators for intra-cellular signalling cascades 
through kinase pathways and also transcriptional factors, which triggers cell proliferation and 
inhibit cell death. Table 1.4.1.1 lists these oncogenes that have a direct link to prostate cancer. 
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Name of oncogene  Function  Reference  
c-myc 
(transcription factor) 
Transcription factor which activates 
genes involved in driving cell 
proliferation and preventing apoptosis  
Swayers 
et al., 2003 
Bcl-2  
(B-cell lymphoma 2) 
Suppresses apoptosis preventing cell 
death  
McDonnell 
et al., 1992 
STAT5  
(signal transducer and activator 
of transcription 5) 
Transcription activators with an anti-
apoptotic function 
Dagvadorj  
et al., 2008 
c-kit/tyrosine kinase  
receptor 
Promotes cell survival, proliferation, 
division, adhesion  and migration  
Paronetto 
et al., 2004 
 
Table 1.4. 1 Oncogenes associated with prostate cancer and their function which is 
enhanced during tumourigenesis. 
 
1.4.2 Tumour suppressors genes 
 
Tumour suppressors, on the other hand are key gatekeeper genes which operate to restrict 
mitosis and are inducers of cell suicide when the need arises. They therefore provide crucial 
stop gaps to ensure correct regulation of cell function and growth. Mutations in tumour 
suppressors lead to a reduction in their protein activity or efficiency and can leave the cell 
vulnerable to further mutations. Unlike oncogenes, tumours suppressors require both alleles to 
be inactivated/altered in order lose normal gene function and therefore are termed as recessive 
in nature. Gene inactivation may result from a hereditary germline mutation of one allele and 
with the wildtype acquiring a damaging mutation later in life, making those individuals with 
germline mutations more susceptible to cancer (Knudson, 1971).   
There are over 20 known tumour suppressors that are inactivated in various cancers, p53 and 
retinoblastoma (Rb) genes are key pathway regulators and are mutated in the majority of 
cancers due to their essential role in delegation of cellular processes, and are therefore the most 
well characterised and studied tumour suppressors. 
The p53 protein is a 53kDa multi-functional transcription factor that binds directly to a DNA 
response element to initiate the synthesis of a vast array of proteins. Identified mutations in the 
core binding domain of p53 have been shown to greatly reduce activity in the majority of p53 
defective cancers (Cho et al., 1994). p53 operates as a central nexus point for signalling of cell 
cycle pathways and orchestrates various protein cascades. p53 concentration of p53 may 
increase and accumulate in the nucleus in response to “danger signals” in the event of DNA 
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breakage. This allows monitoring of cellular stress and damage to DNA which subsequently 
leads p53 to override cell proliferation signals, initiat cycle cell arrest and trigger apoptotic 
pathways, thus having an anti-oncogenic function within the cell. Its own regulation is tightly 
controlled by MDM2, a ubiquitin proteolysis enzyme that operates on a controlled feedback 
loop mechanism when the concentration of p53 rises. Often referred to as “the guardian of the 
genome” p53 has a fundamental role in preserving cell integrity for future division and cell 
growth, including initiation of DNA repair (Kastan et al., 1992; Meyer et al., 1999; Smith and 
Seo, 2002). 
Like p53, the protein encoded by the Rb gene interacts with a many cell cycle proteins and on 
integration of these signals, determines whether the cell undergoes division and growth. In 
cancer, the deactivation of the Rb protein prevents its effective suppression of S phase, 
promoting transcription factors of the E2F family. As a consequence, the cycle cell can 
progress from G1 phase to the S phase of cell proliferation (Lees et al, 1993).  Interestingly, 
both tumour suppressors are targeted for degradation by oncogenic viruses, most notably by 
Human papillomavirus (HPV) for which a national vaccination programmed for all girls aged 9 
to 18 was introduced in 2008, in order to prevent cervical cancer in the UK. Here E6 and E7 
viral protein bind to the tumour suppressors gene fraction of p53 and Rb protein respectively 
(Scheffner et al, 1990; Cheng et al, 1995). Table 1.4.2 lists these tumour suppressors genes that 
have been associated with human prostate cancer.  
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Name of tumour suppressor Function Reference  
Rb (Retinoblastoma) Key regulator for entry into cell division 
Kubota  
et al., 1995 
p53 
(Tumour suppressor protein 
p53) 
Key regulator of cell cycle, division and 
apoptosis 
Gumerlock 
et al., 1994 
PTEN 
(Phosphatase and tensin 
homolog) 
Involved in regulating AKT/PKB pathway 
Li 
et al., 1997 
GSTP1 
(Glutathione S-transferase P1) 
Detoxify environmental carcinogens and 
oxidants preventing DNA damage 
Nelson  
et al., 2004 
p27/KIP1 
(Cyclin-dependent kinase 
inhibitor 1B) 
P27 controls cell cycle progression at G1 
Kyprianou 
et al., 1997 
NKX3.1 
(NK3 homeobox 1) 
Transcription factor involved in prostate 
development 
Shen  
et al., 1999 
KLF6 
(Kruppel-like factor 6) 
Transcriptional activator 
Dong  
et al., 2003 
BRCA2 
(breast cancer 2, early onset) 
Genome stability homologous repair pathway 
for double stranded DNA repair 
Mitra  
et al., 2008 
 
Table 1.4. 2 Tumour suppressors specific to prostate cancer and their normal function 
which are lost during tumourigenesis.   
 
In most cancers, tumours develop and sustain the ability to continually proliferate in the 
absence of mitogenic growth signals. Tumour cells have been shown to increase pro-
proliferation signalling using a number of mechanisms; briefly, they may have the capacity to 
produce their own growth ligands resulting in autocrine induced proliferation. In addition to 
this, tumour cells may disrupt signalling in normal cells within the surrounding stroma to 
induce the production of growth factors to promote tumour growth, demonstrated by the up 
regulation of hepatocyte growth factor, by fibroblasts in breast carcinoma (Cheng et al., 2008). 
Tumour cells may also upregulate the synthesis of growth factor receptors presented on their 
cell surface, the HER2 receptor being a frequent example and one that has been successfully 
utilised as a therapeutic target in HER2+ breast cancer. Structural alterations in growth factors 
and their receptors which enhance the rate of activation of their subsequent downstream 
pathways also sustains cell proliferation. Not only do tumour cells increase mitogenic 
signalling through growth factors and their receptors, they also maintain “pro-growth” 
conditions by becoming increasingly insensitive to anti-growth signals (O'Regan et al., (2012). 
An important aspect of cell maintenance is programme cell death which serves to eliminate 
aberrant cells from the population. This in essence is an anti-cancer defence which must be 
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overcome by tumour cells in order to continually replicate. Evading intrinsic apoptotic 
pathway activation by bypassing homeostatic sensors (p53, Bcl-2 family proteins) and their 
subsequent apoptotic effector molecules (death signals and caspases) means an additional bias 
toward cell growth (El-Deiry and Jin 2005).  
 
In order to survive and sustain continual turnover, tumour cells must achieve replicative 
immortality unlike cells which normally (not-transformed) undergo a predefined number of 
division cycles. Telomeres are composed of multiple base-pair sequences located at the 
chromosomal ends, although they hold no genetic information, they protect the ends of 
chromosomes and determine the cell’s capacity to divide in that after every round of division 
they shorten and eventually trigger cell senescence. Tumour cells increase the synthesis of a 
telomere extending polymerase (telomerase) and are therefore able to counter the senescence 
countdown and become in effect “immortalised cells”. Protein components of telomerase, in 
particular TERT, have been shown to have a much more diverse involvement in support of cell 
proliferation, anti-apoptosis and DNA damage repair all of which aid tumourigenesis. Recently 
hTERT has been considered as a target for cancer therapy, especially immunotherapy (Thomas 
et al., 2002; Yang et al., 2012). Continual proliferation allows tumour cells to monopolise 
nutrients and oxygen and removal of waste produces by the formation of tumour associated 
neovasculature. To achieve this, tumour cells upregulate angiogenic inducers such as vascular 
endothelial growth factor (VEGF) and suppress their counterpart inhibitors which results in the 
initiation of endothelial cells that form the basis for blood vessel formation. This process is 
referred to as the “angiogenic switch” and is activated in metastatic disease and has been 
considered a viable target for therapy. By using inhibitors to VEGF (bevacizumab) and its 
receptor (sunitinab) to target tumour driven angiogenesis, clinical observed responses have 
been transient, as increasing evidence suggests tumours inhibited by angiogenesis go on to 
enhance activation of invasion and metastasis around surrounding normal tissue to access 
existing vasculature (Bergers and Hanahan 2008; Ellis and Hicklin (2008).  
Tumour cells have a final acquired capability which is absent in the majority of normal cells, 
their ability to invade surrounding tissue, pass through the blood and lymphatic system and 
colonise distant tissue. This complex multistage process is termed invasion and metastasis, and 
the cause of cancer lethality. Briefly, tumour cells begin to invade by penetrating and moving 
through the basement membrane of surrounding local tissue by releasing proteases such as 
matrix metalloproteinases (MMP’s) and alter their expression of cell adhesion (intergrin) 
molecules to favour invasion. Degradation of the surrounding extracellular matrix (ECM) 
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allows tumour cells to gain access to surrounding blood and lymphatic vessels (intravasation) 
and be transported through these networks and disembark at distant organs (extravasation). 
Tumours adapt to the organs specific microenvironment may proliferate, initiate angiogenesis 
and metastasise once more (Itoh and Nagase, 2002; Talmadge and Fidler, 2010). 
 
 
 
Figure 1.4.2.1 Schematic of metastasis cascade process. 
(Adapted from Nature Reviews Cancer; Wirtz et al.,2011) 
 
Intensive research into tumourigenesis over the last decade has begun to reveal further tumour 
hallmarks that explain tumour enabling characteristics and how they survive or evade 
elimination by the body’s own defence mechanisms. The increasing genomic instability of 
cancer cells allows rapid cell turnover and gives them a selective advantage over other cell 
populations. This is achieved by the tumour cells ability to dismantle genomic maintenance 
machinery and subdue the cells genomic surveillance systems avoiding cell suicide. Another 
emerging hallmark is the deregulation of cellular metabolism, namely the tumour cells ability 
to reprogramme and redirect cellular energy towards fuelling cell growth and division. At the 
forefront of research into tumourigenesis and strategies for therapy, is to better understand the 
role that the immune system plays in supporting tumour growth. Tumour cells are able to 
manipulate immune activity in the surrounding vicinity to circumvent immune destruction of 
the tumour, and to promote tumour growth through inflammation. The ways in which immune 
evasion and tumour expansion is achieved will be discussed below how by harnessing the 
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body’s most important defence mechanism; the immune system, opportunities to oppose 
cancer can be exploited. 
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1.5 The immune system 
 
The immune system is comprised of cells, originating from precursor haematopoietic stem 
cells produced in the bone marrow which under influence from specific cytokine stimulations 
are able to differentiate into a distinct array of myeloid (differentiating into granulocytes and 
monocytes) and lymphoid progenitor cells (T and B lymphocytes), which differentiate further 
into specialised subsets. For T lymphocytes repertoire generation and selection take place in 
the thymus, an essential process that selects against T-cells recognising cognate “self-
antigens”. The immune system has a principal function to survey and eliminate any potential 
dangers to the body arising mostly from incoming pathogens. There are two types of the 
response mechanisms which work together to achieve this: the innate and the adaptive 
response. 
1.5.1 Innate immunity 
 
The innate arm is referred to as the first line of defence as it constantly “seeks and destroys” 
any posing threat to the body. The innate system operates in a primitive response context 
which is comprised of a series of transmembrane receptors, called Toll-like receptors (TLR’s) 
located on dendritic cells (DC’s) and macrophages. TLR’s are a family of 13 pathogen 
associated molecular pattern recognition receptors which recognise a diverse range of 
molecules typically essential to the function of invading pathogens but are not present in host 
cells, examples include bacterial flagella (recognsing TLR 5) and lipopolysaccharides 
(reconising TLR 4) and ligands for nucleic acids derived from viruses (specific for TLR 3 
and TLR 7) (Ouchi and So 2010). Stimulation of macrophages through activation of their 
TLR leads to the release of inflammatory response elements which recruit phagocytic cells 
for the elimination of target pathogens and infected host cells. This type of response is 
dependent on TLR recognition of pathogen associated molecules and provides an immediate, 
albeit fixed, transitory immune response (Seong & Matzinger., 2004). 
1.5.2 Adaptive immunity 
 
In comparison, on encountering pathogens, the adaptive response requires an array of 
specialised cells (T cells and B cells and their subsets) all of which have specifically 
engineered receptors to recognise small segments of peptides which in this context are termed 
antigens (Ag’s). Through presentation of Ag’s by DC’s, T and B cells undergo specific cell 
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expansion and trigger a diverse immune response towards those pathogens carrying the same 
Ag resulting in pathogen destruction through the production of antibodies (B cells, humoral 
response) and the activation of “immune” cells through MHC-peptide and cytokine facilitated  
stimulation (T cell, cell mediated response).  This is a far more flexible response mechanism 
to the innate system, which also retains memory cells which act immediately in response to 
any future encounter with the same antigen/pathogen to trigger a much more rapid response 
(González et al., 2008; Moretta & Moretta, 2004)                
Despite their different mechanisms of action, the humoral and cell mediated responses are 
coordinated through 3 types of professional antigen presenting cells (APC’s), these are 
macrophages, DC’s and B cells which scour the body sampling the surrounding environment, 
internalising and processing pathogen Ag’s and finally presenting these Ag’s on their cell 
surface in the context of major histocompatibility complex (MHC) molecules to T cells. In 
order to mobilise a T cell response, DC’s must undergo alteration from an immature to a 
mature state (Salio et al., 2001; Medzhitov, 2001). 
This switch occurs on encounter with a pathogen and the release of interleukin-1 (IL-1) and 
Tumour Necrosis Factor- α (TNF-α), which causes mature DC’s to migrate from the 
peripheral tissue to the lymphatic system. Full maturation of DC’s occurs through 
interactions with co-stimulatory molecules CD28/CD80-86 and CD40/CD40L present on 
both APC’s and T-cells, following which appropriate presentation of Ag’s can take place in 
the context of MHC presentation (Moretta & Moretta, 2004).  
1.5.3 Major histocompatibility complex (MHC) 
 
Human leukocyte antigen (HLA) or MHC molecules are presented on the surface of cells and 
provide the correct presentation context for T cells to recognise Ag’s and initiate a cascade of 
immune responses. MHC are subdivided into MHC class I and MHC class II antigens 
according to their structure. MHC class I comprises of a transmembrane polypeptide α-heavy 
chain component consisting of 3 domains (α1, α2, and α3) and an associated β2-
microglobulin (β2m) component. MHC class II consists of two transpolypeptide chains α-
chain (comprising of α1, α2) and β-chain (comprising of β1, β2). Highly polymorphic HLA 
gene combinations, where each individual inherits two sets of each gene, gives rise to a very 
diverse range of MHC molecules. MHC class I antigens are present, with very few 
exceptions, on all nucleated cells and are able to bind endogenous peptides 8-11 amino acids 
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in length and present these to CD8+ T cells. MHC class II are present on all APC’s or can be 
induced on other cells such as epithelial cells by cytokine stimulation, and are able to present 
exogenous peptides 12-25 amino acids in length to CD4+ T cells. Ag’s that are presented by 
the MHC complex share a unique binding motif with T cell receptor (TCR) molecules found 
on CD8+ and CD4+ T cell sub populations. Only when correct recognition between MHC, 
Ag and TCR occurs along with corresponding CD8+ and CD4+ glycoprotein and the correct 
co-stimulatory signal (CD28 and CD80/CD86) interaction can T cells become activated. A 
lack of co-stimulation between these signals leads to T cell anergy towards that particular Ag. 
(Harding et al., 1992; Bennett et al., 1997; Ossendorp et al., 1998; Wang & Livingstone, 
2003).    
T cell activation on encounter of Ag displayed in the correct MHC complex leads to clonal 
expansion of T cells possessing the specific receptor for the Ag. Activated T cells proliferate 
into active effector T cells with specialised functions as either cytotoxic T lymphocytes 
(CTL’s) (CD8+) and/or T helper (Th) cells (CD4+) responding to MHC class I and II 
antigens respectively. CD8+ cell are described as the fundamental component required for for 
direct elimination of tumour cells. Under the influence of IL-2 they are able to undergo clonal 
expansion not only with amplified expression of the TCR matching the Ag of interest but also 
expression of Fas ligand (FasL). Activated CD8+ T cells are then able to migrate throughout 
the body and target MHC class I receptors presenting the same antigenic peptide. Once CTL 
recognise tumour cells expressing the antigen they are able to engage the target and release 
cytotoxin (perforin) into the tumour to initiate caspase signalling cascades which leads to 
tumour cell death. CTL cells can also induce apoptosis in tumour cells via the FasL/Fas death 
receptor pathway. FasL also activates caspases resulting in degradation of DNA structure and 
deregulation of the cells cytoskeleton framework leading to cell arrest or cell suicide. 
(Porakishvili et al., 2004; Stalder et al., 1994; Thomas & Hersey, 1998) 
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Figure 1.5.3.2 Overview of the three phases of cancer immunoediting.  
 (Adapted from Dunn et al., 2004). 
 
T helper (Th) cells originating from CD4+ T cells support the cellular response to Ag by 
orchestrating the attack led by CD8+ T cells. Upon presentation of exogenously processed 
Ag’s through MHC class II, CD4+ T cells secrete various IL’s and IFNγ cytokines leading to 
the production of subpopulations of Th1, Th2 and Th memory cells. These subset are critical 
in determining the nature of the immune response through cytokine dependent cell 
stimulation and ultimately dictating whether the response initiated is predominantly humoral 
(Th2) or cell mediated (Th1). The release of IL-2 and IFNγ cytokines by Th1 cells is 
favourable to activation and expansion of CD8+ T cells, bolstering the CTL response and 
promoting them to proliferate to assist in maintaining a longer CTL response and avoiding T 
cell anergy. Th1 cells release IFNγ which also promotes the production of IL-2 and activation 
of APC’s, which in turn operates in a positive feedback loop to maintain the Th1 response. 
Conversely, IFNγ works to hinder IL-4 production which subsequently suppresses Th2 cell 
development. Taken together, immunomodulation of cell mediated immunity through 
cytokine release mechanisms mean that Th responses are mutually inhibitory and function as 
a counter balance to initiate T-cell activity. Given that Th1 driven CTL responses can 
27 
 
distinguish between a tumour cell and a normal “self” somatic cell with the added advantage 
of immunological memory (the humoral response is unable to make this crucial 
discrimination), it stands to reason that a Th1 response is advantageous in eliminating tumour 
cells (Sica & Mantovani, 2012; Martinez et al., 2009)  
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1.6 Tumour immunology  
 
The immune system is able to specifically detect, target and then eliminate newly arising 
tumour cells in the body, and this process is therefore termed immunosurveillance. This is 
believed to occur throughout life, however, tumours still arise which persistently and 
successfully evade these detection methods and continue to proliferate to form clinically 
detectable cancers. In response to the surveillance mechanisms employed by the immune 
system, tumours have been shown to use several “escape” mechanisms to subdue or avoid 
immune attack. Tumours may down regulate the production of MHC class I Ag’s presented 
to T cells with in some instances the complete loss of MHC class I molecule on their cell 
surface, achieved by mutations or loss of gene components that assemble to produce the 
complex (β2m, TAP, HLA gene and MHC heavy chain) (Janeway, 2001) 
Secondly, tumour cells can reduce surface expression of a particular tumour Ag and lose the 
immunodominance of that Ag, whereby a subclass of previously immunorecessive tumour 
Ag’s emerge whereby immune T-cells are less able to target tumours cell due to less effective 
MHC/TCR interactions with the new antigenic epitopes. Tumour cells may also begin to 
circumvent the activation of death signalling pathways such as FasL and TRAIL found on the 
tumour cell surface by deactivating them (Thomas and Hersey, 1998). This may result in a 
state of T-cell anergy through lack of correct receptor co-stimulation of activated T cells. 
Finally, tumour cells subdue the immune response by releasing immunosuppressive 
cytokines, (increasing VEGF, IL-10 and TGFβ and reducing the production of IL-2 and IL-
12) generating an environment that favours tumour expansion without immune constraints 
(Khong and Restifo 2002). 
Building on this notion of immunosurveillance, Burnett and colleagues (Burnett et al., 1970) 
proposed the theory of immmunosurveillance and more recently the concept of 
immunoediting. It was proposed that natural killer (NK) cells scour the body disposing of 
tumour cells that pose a potential cancer threat. Observations of an increase of cancer in 
immunocompromised individuals such as those with immune deficiencies and supressed 
immune systems such as transplant patients, added further weight to the idea of 
immunosurveillance, which operates through activation of danger signals or tumour specific 
markers resulting in the destruction of tumour and a predominantly Th1 response. If however 
the tumour is only partially cleared, the remaining cells are maintained in equilibrium. 
Immune editing determines the antigenic composition of the new population of tumour cells 
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through an immune selection process. Here, selection pressures applied by the immune 
system allow tumour cells most resistant to immunity to emerge and escape through various 
mechanisms in a “Darwinian-like” evolutionary fashion (Schreiber et al, 2002).   
Evidence suggests that the immune response plays a further role in tumour formation in that 
the response may in fact stimulate the growth of tumour cells by inducing Th2 T-cell 
responses. This can result in the infiltration of mast cells into some tumours and tumour cells 
themselves may be incapable of stimulation a strong immune response (Imada et al., 2000). 
Here, tumour cells use the same pro-growth mechanisms that promote wound healing to 
maximise their own growth. 
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1.7 Tumour antigens 
1.7.1 Tumour associated antigens 
  
As a direct consequence of genetic mutation described in earlier in section 1.4 various tumour 
associated protein products consisting of endogenously processed peptides are presented as 
Ag’s on the cell surface of tumour cells have been found to be unique in their expression on 
tumour cells. More significantly, these tumour associated antigens (TAA’s) provide viable 
targets for their applications as in immune based therapy against tumour cells.  
Over the past decade many TAA’s have been identified across a whole range of cancers, 
theses TAA’s can be broadly separated into five categories. 1) Normal (unmutated) self Ag’s 
that are re-expressed in large quantities in tumour (MAGE-1, NY-ESO-1) also referred to as 
cancer/testis Ag’s due to their unique expression in specific tumours, and in 
immunoprivileged sites (testis and placenta) or in embryonic stages (CEA) (Boon et al,  
1992; Chen et al., 1997). Genes encoding for these Ag’s are usually silent in normal tissue 
however become activated in tumours. 2) TAA’s are differential Ag’s that are derived from 
tissue specific Ag’s which are over-expressed in tumours and present in low levels in tissues 
(gp100, MART/melan) (Schwartzentruber et al., 2011). 3) Over-expressed normal 
(unmutated) Ag’s found in tumours, these can be amplified products of genes (HER2/neu, 
hTERT) (Tsai et al., 1997). 4) Oncogene and tumour suppressor gene products and genes as a 
result of translocations that are expressed by the tumour (CDK4, ras, p53, bcr/abl). 5) Virally 
encoded proteins that can be expressed on the tumour cell surface (HPV derived E6 and E7 
Ag’s) (Song et al., 1999; Kawashima et al., 1998; Rojas et al., 2005). It is considered 
important to identify new target antigens for immunotherapy, in order to formulate a 
vaccination starategy.  
In order to combat tumour cells, cancer immunotherapy strategies must counteract various 
immune evasion manoeuvres described earlier. The crucial aspect of all strategies are to 
target tumour cells by activation of APC’s and T cells by augmenting the existing response 
which has been suppressed by tumour cells. On this basis, the identification of tumour Ag’s 
are critical that have been shown to already elicit an antibody response in patients; p53, for 
example, provides evidence that an antibody and cell mediated response can be achieved as 
anti-tumour targets.  
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Tumour antigen  Expression in tumour  Normal tissue 
distribution  
Oncofetal antigens:  
AFP  
CEA  
Hepatocellular carcinoma  
Colorectal carcinoma  
None  
None  
Oncoviral antigens:  
EBV  
HPV(E6/E7)  
HBV  
Burkitt’s and Hodgkin’s 
lymphoma Cervical 
cancer, head and neck  
Hepatocellular carcinoma  
-  
-  
-  
Tumour-specific unique 
antigens:  
Bcr/Abl  
Ig idiotype  
Chronic myeloid 
leukaemia  
B cell non-Hodgkin’s 
lymphoma  
None  
None  
Cancer-Testis antigens:  
MAGE, BAGE,GAGE 
families  
NY-ESO-1  
Multiple  
Multiple  
Testis  
Testis  
Overexpressed antigens:  
Her-2  
Muc-1  
p53 (mutated)  
p53 (wild type)  
Survivin  
WT-1  
Breast, ovarian, lung  
Breast, ovarian  
Pancreatic, colon, lung  
Multiple  
Multiple  
Gastric, lung, HCC, 
leukaemia  
Ubiquitous (low)  
Breast  
None  
Ubiquitous (low)  
Ubiquitous (low) None  
Differentiation antigens:  
Melan-A/Mart-1  
gp100  
Tyrosinase  
PAP, PSA, PSMA  
Melanoma  
Melanoma  
Melanoma  
Prostate  
Melanocytes  
Melanocytes  
Melanocytes  
Prostate  
 
Table 1.7.1.1 Tumour associated antigens.    
A list of the major classes of TAAs found in cancer; examples showing the types of 
malignancies in which they can be found and their expression in normal tissue. 
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1.7.2 SEREX technique and identification of prostate tumour antigens 
 
An attractive category of tumour antigens, first discovered in the analysis of T cell recognised 
epitopes, has been referred to as cancer testis antigens.  CTAs are expressed in variable 
proportions, approximately 10-40 %, of a wide range of different human tumour types, and 
their unique expression pattern makes them attractive targets for vaccination purposes.  CTAs 
are derived from non mutated genes that are expressed in various tumours but not in normal 
tissues except testis, embryonic ovaries and placenta (Osterlund et al., 2000) (Li et al., 2004; 
Scanlan et al., 2004).  These genes are attractive candidates for tumour immunotherapy 
because of their unique expression pattern and because their expression can be shared by 
multiple tumour types (De Plaen et al., 1994).  Additionally, induction of CTL responses does 
not cause a risk of inducing autoimmunity because CTAs in testis are expressed by 
spermatogonia and spermatocytes which do not carry HLA molecules, hence the CTAs 
cannot be expressed by these cells and recognised by antigen specific CTLs (Coulie., 1997). 
One of the first CTAs identified via a serological screening approach was NY ESO 1.  NY 
ESO 1 belongs to an expanding family of immunogenic testicular antigens that are aberrantly 
expressed in human cancers in a lineage non-specific fashion (Gure et al., 1997).  With the 
exceptions of SCP 1, OY TES-1, and CT15/fertilin β, the biological function of most CTAs is 
not known. 
The SEREX technique (Serological analysis of cDNA expression libraries) first devised in 
1995 (Sahin et al 1995), combines serological analysis with antigen expression and cloning 
approches to identify, in this instance, human tumour antigens which elicit IgG antibodies. 
This method involves extraction of mRNA from tumour derived tissue which is then 
expressed in a λ-phage display vector to create a cDNA expression library; these libraries are 
screened with patient sera, the positive colonies are isolated, cloned and sequenced and are 
finally put forward for DNA databank search.  This then allows further sequence analysis to 
be performed to define tumour antigens, the identification of any gene abnormalities, 
assessment of mRNA expression patterns in normal, benign and malignant tissues and 
frequency of antibody responses relative to disease status.  
By applying this principle in a modified SEREX approach, cDNA expression libraries were 
constructed from normal human testicular mRNA and were used to screen pooled allogeneic sera 
from prostate cancer patients in order to identify novel tumour associated antigens. Following 
this, positive clones underwent databank searches, analysis of gene anomalies, and assessment of 
33 
 
mRNA expression in normal and malignant tissue. A panel of serologically defined antigens 
expressed human prostate cancer cells were identified, included T21 and the findings published in 
2007 (Miles et al., 2007). Further examination of T21 serological reactivity using recombinantly 
expressed protein showed T21 reactivity with sera from 5/10 prostate patients whereas no 
reactivity was observed in 10 healthy individuals with benign prostatic hyperplasia (BPH). RT-
PCR using cDNA reverse transcribed from whole tissues also supported the notion of a 
potentially good immunotherapeutic target with expression restricted to normal testis, kidney, 
gastric and prostate cancer, mild expression in BPH and little or no mRNA expression observed 
in normal essential tissues examined. Later, T21 was found to share significant sequence 
similarity with a centrosomal protein called CEP290 to which the presence of CEP290 antibodies 
has been previous reported in a number of malignancies (Eichmuller et al., 2001; Chen & Shou, 
2001). To date, SEREX technique allowed identification of novel tumour antigens including 
T21, T128 and Pr genes published in 2007 (Miles et al., 2007).   
1.7.3 Previous investigation of T21  
 
In-silico analysis revealed the T21 DNA sequence to be situated on chromosome 12q21.33 
and further sequence analysis showed the full nucleotide sequence to be 2797bp in length, 
encoding a novel 524 amino acid protein. Structurally T21 was found to consist of 19 exons 
with 12 exons covering the coding region of the gene.  
Expression analysis studies, using both conventional and RT-qPCR demonstrated the 
aberrant expression of T21 mRNA in various human neoplasms including gastric, kidney, 
and prostate cancer tissues and cell lines. 
Mild expression in BPH was observed for T21 but low or no expression was observed in 
other normal tissues examined (Miles et al., 2007). Although T21 is not an X chromosome 
linked gene, in view of the restricted expression pattern of T21 with expression in germ cells 
of the testis and a variety of malignant tissues but generally not in other normal tissues, the 
presence of a SPAN-X domain and the antigenic property of T21, it has been tentatively 
assigned to the cancer/testis antigen family.  
It has also been previously shown that the expression of prostate cancer-associated antigens 
can be diluted out in heterogeneous tissues when RNA is extracted from whole tissues and 
not specifically from prostate cancer glandular epithelium. Using, laser-capture micro-
dissected material to obtain pure populations of malignant glands and benign prostatic 
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epithelium and stroma, a significant up regulation in T21 expression was found in cancerous 
glands. 
Initial immunohistochemistry studies using an antibody directed against T21 were performed 
and demonstrated its specific expression at the protein level in tumour tissue with no or little 
expression found in normal and benign tissues. In addition T21 protein expression, as 
assessed using the same anti-T21 antibody, was found to be associated with tumour grade and 
significantly with tumour stage. Further studies have also demonstrated that knocking down 
(silencing) the function of T21 in a prostate cancer cell line reduces the proliferation of these 
cells significantly, indicating T21’s potentially crucial role in cell survival (Miles et al., 
2012). 
Interestingly, it was subsequently discovered that T21 may be a splice variant of another 
protein called CEP290 (mutations of which have been associated with Joubert syndrome) and 
that a portion of a CEP290 intron was now part of the coding region of the T21 variant 
making this coded sequence of T21 unique (exon 10). 
CEP290 is a 93.2kb gene located on chromosome 12q21.32, it spans 54 exons and forms a 
large protein product of 290kD and was first identified from proteomic screening of a human 
lymphoblast cell line. Although the exact role of CEP290 protein is still largely unknown, it 
has been shown to play a role in the centrosomes and basal bodies, cilia function and has 
been shown to associate with microtubule-based transport of proteins including centrin, 
gamma-tubulin, KIF3A, ninein and pericentrin (Chang et al., 2006). It has also been shown to 
interact with PCM1 a trafficker of centrosomal proteins and has been linked with maintaining 
spindle pole integrity prior to and during cell mitosis (Rhee and Kim 2010).  
Further investigation using a custom designed mono-specific polyclonal antibody raised in 
rabbit designed in coding exon 9 of T21 with the peptide sequence: 
(VELERQLRKENEKQKNEL) showed protein expression to be restricted to normal 
stomach, ovary, breast and prostate with greater expression demonstrated in numerous cancer 
tissues. Protein expression has been extensively studied in prostate cancer in which this 
laboratory reported significant over expression of T21 in prostate cancer glands compared 
with those derived from benign tissue. Additionally, expression was positively associated 
with pathological stage of tumours and suggested a correlation with increasing Gleason grade 
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and PSA recurrence (Miles et al., 2012). Moreover, T21 was found to be highly homologous 
to CEP290 with the exception of a unique T21 region derived from a CEP290 intron. 
1.7.4 The strategy of gene knockdown to determine the gene function: 
Gene knockdown technology using small interferon RNA (siRNA) was first described in 
1999 by Baulcombe's group when they showed three types of transgene-induced post-
transcriptional gene silencing and one further example of virus-induced post-transcriptional 
gene silencing. They analysed and detected antisense RNA complementary to the targeted 
mRNA in plants. Their findings showed that the RNA molecules have constant size which 
was estimated at 25 nucleotides (Hamilton and Baulcombe, 1999). Gene knockdown or 
“mRNA silencing’’ is a regulatory cellular mechanism using RNA interference (RNAi) 
which is recently elucidated effectively. This useful technique is used mainly to disrupt 
unknown coding sequence and observe which structure and/or function will be resulting from 
the knockdown (Capecchi, 1989; Napoli 1990). Full knowledge of the genome requires 
knowledge of the function of each of the gene products of the putative genetic coding 
sequences. Effective studies using ribozymes directed against the mRNA expression product 
of a targeted gene have shown the ability to down-regulate or ‘‘knockdown’’ the expression 
of these targeted genes (Sokol & Murray, 1996).  
RNA interference (RNAi) is an RNA-dependent gene-silencing phenomenon which is 
initiated by ∼20-bp double-stranded RNA in the cytoplasm (Sontheimer and Carthew, 2004; 
Liu et al, 2004; Meister and Tuschl, 2004). The activation of RNAi can be exogenous or 
endogenous. A synthetic small interfering RNA (siRNA), for example, is considered to be 
exogenous RNAi. In contrast, siRNA that is expressed from its respective gene within the cell 
is represented as endogenous RNAi as well as pre-micro RNA (miRNA)-like short hairpin 
RNA (shRNA) (Brummelkamp et al, 2002; Miyagishi and Taira, 2002; Zheng et al, 2004). 
Both short hairpin RNA (shRNA) and small interfering (siRNA) are endogenously 
transcribed in the nucleus and then exported to the cytoplasm, where the Dicer enzyme will 
split or (cleave) the characteristic stem–loop of shRNA (Hannon and Rossi, 2004; Mello and 
Conte, 2004). siRNA and its shRNA precursor are involved in pathways which converge at 
RNA-induced silencing complex (RISC) and, subsequently, the sense strand from the siRNA 
duplex will be removed and then and then degraded (Figure 1.7.4.1). Therefore, the antisense 
strand within RISC can recognise sequence-homologous RNAs and mediate target specificity 
(Sontheimer and Carthew, 2004; Zhou et al, 2006). 
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Figure 1.7.4.1: Schematic representation of RNAi pathways and how both siRNA and 
shRNA are generated within cells. 
(Adapted from Nucleic Acids Research, Jin et al, 2012) 
 
1.8 Aims of the study 
 
The serological identification of novel tumour antigens by screening with prostate cancer sera 
is an interesting development requiring further investigation. The aims of this study were 
therefore to further characterise T21 at its molecular mechanism and to determine its 
potential role in cancer by: 
• Study the expression of the T21 tumour antigen in prostate cancer cell lines, prostate 
cancer cell by characterising T21 at the molecular level and understand its 
relationship with the CEP290 gene. 
• Determine T21 function and its involvement in tumourigenesis by: 
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• Investigating the effect of T21 knockdown on key cellular pathways through 
the analysis of genes expression profiles obtained by Next Generation 
Sequencing (NGS) 
• NGS data pathways modelling using bioinformatics tools 
• Pathways analysis using molecular and proteomics approaches 
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2 CHAPTER TWO: Materials and Methodology 
2.1 Materials: 
2.1.1 Laboratory materials and equipment 
2.1.1.1 Reagents and a list of suppliers 
Culture media and supplements Supplier 
DMEM Lonza 
KSFM Invitrogen 
OPTIMEM Invitrogen 
RPMI 1640 Lonza 
Blasticidin Invitrogen 
Fetal Calf Serum (FCS) Perbio Thermo Fisher 
HAM-F-12K 
HEPES buffer 
Lonza 
Lonza 
L-glutamine Lonza 
ddPBS Lonza 
 
 
 
Cell culture reagents Supplier 
Dimethyl Sulphoxide Hybri-Max (DMSO) Sigma 
INTERFERin Polyplus Transfection 
Lipofectamine 2000 Invitrogen 
Trypsin/Versene Lonza 
Trypan blue Sigma 
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Chemical reagents Supplier 
Acrylamide Geneflow 
Agarose Bioline 
Ammonium persulphate (APS)  National Diagnostics 
Bovine serum albumin (BSA)  Calbiochem 
Chloroform Sigma 
Decon 90 Decon Laboratory Ltd 
Sodium Deoxycholate Sigma 
Dithiothreitol (DTT) Sigma 
dNTP Bioline 
DNA ladders (1kb and 100bp)  Promega 
Dried marvel skimmed milk  Premier Brands 
Ethanol  BDH 
Hydrochloric acid (HCl) Fisher  
Isopropanol  Fisher 
Liquid Nitrogen British Oxygen Company 
Methanol Fisher Scientific 
M-MLV RT and 5X Reaction Buffer Promega 
Oligo(DT) 15 primer Promega 
Paraformaldehyde  Sigma 
Phosphate buffered saline (PBS) tablets Oxoid  
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Consumables Supplier  
10ml syringes Becton Dickenson 
Sterile hypodermic needles 25 G Becton Dickenson 
0.5/1ml needles and syringes Becton Dickenson  
15ml Universal tubes Bibby Sterilin 
Microscope glass slides  SLS 
24 well plate round cover slips SLS 
0.2 µm filters   Sartorius  
Presept  Johnson and Johnson 
RNasin Ribonuclease Inhibitor Promega 
RNA STAT-60 AMS Biotechnology 
Sodium Chloride (NaCl) Fisher 
Sodium dodecyl sulphate (SDS) Sigma 
Sodium fluoride Sigma 
Sodium orthovanadate Sigma 
Stacking gel buffer for SDS gels Geneflow 
Sybr Green SuperMix BioRad 
TEMED Geneflow 
Tris-base Sigma 
Tween20 Sigma 
Western-C Precision Plus Mwt marker BioRad 
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Pre-filter separation columns 70 µm Miltenyi Biotech 
LS Columns Miltenyi Biotech 
5ml/10ml/25ml plastic pipettes Sarstedt 
15ml/50ml polypropylene tubes Sarstedt 
24-well/96-well tissue culture plates Sarstedt 
25cm
2 
/75cm
2 
/
 
175cm
2 
tissue culture flasks Sarstedt 
0.5ml/1.5ml eppendorf tubes Sarstedt 
10µl/200µl/1000µl Pipette tips Sarstedt 
Plastic pasteur pipettes Sarstedt 
1.5ml Cryovials TPP 
10µl/20µl/200µl/1000µl Pipette tips Sarstedt, Starlabs, Deuchter 
Scientific 
 
2.1.1.2 Equipment 
 
All glassware and plastic boats were washed out using presept then rinsed and soaked in 
ddH2O overnight and left to dry then sterilised using an autoclave prior to use. 
Equipment Supplier 
Autoclave Rodwell 
Bench top vortex mixers Scientific Industries 
Cryostore, Cryo 200 Forma Scientific 
Cell Harvester, Filtermate Harvester Packard 
Centrifuges (MSE Mistral 2000R) Sanyo 
43 
 
Class II safety cabinets, Microflow biological 
safety cabinet 
 
Walker 
ELISPOT Reader, Immunospot Analyzer Cellular Technology Ltd. 
-20 freezer Lec 
-80 freezer, Ultima II Revco 
4°C fridge Lec 
Fluorescence microscope Olympus BX51 
4°C refrigerated centrifuges Eppendorf/Sanyo 
Haemocytometers Weber 
Incubators CO2 water jacked incubator Forma Scientific 
Light microscopes  Nikon/Olympus 
Light microscope camera  Nikon 
MACSMix Tube Rotator  Miltenyi Biotech 
MACS MultiStand Miltenyi Biotech 
Microcentrifuge, Microcentraur MSE 
MidiMACS Separator Milteny Biotech 
Nanodrop 8000 Spectrophotometer  Thermo Scientific 
PALM Laser-capture microdissector (LCM) Carl Zeiss 
PCR Workstation Cabinet Grant 
pH meter Metler Toledo 
Plate rocker  
Pipettes and multichannel pipettes 
VWR 
Gilson, Star labs, Eppendorf 
44 
 
Real Time qPCR Thermal Cycler Qiagen 
Ultra Sonicator VWR 
UNO-Thermoblock Biometra 
Water baths  Grant 
 
Buffers 
Buffers used for cell culture 
Trypan Blue for cell count 
0.1% (v/v) solution Trypan Blue in DPBS. 
 
 
Immunochemical Reagents 
Antibodies 
Primary: 
 
Anti T21 polyclonal Ab (Rabbit) 
 
Pacific Immunology 
Anti Unique T21 polyclonal Ab (Rabbit) Pacific Immunology 
Anti CEP290 polyclonal Ab (Goat) Everest Biotech 
IgG Rabbit Isotype control Serotec 
IgG Goat Isotype control R&D Systems 
Anti-Beta actin Ab (Rabbit) Cell Signalling 
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Secondary: 
Alexafluor 488 – goat anti-rabbit IgG Invitrogen 
Alexaflour 568 – donckey anti-goat IgG Invitrogen 
Rabbit anti-goat-HRP secondary Ab Dako 
Swine anti-rabbit-HRP secondary Ab Dako 
  
Reagents and buffers  
VectorShield Mounting Media with DAPI   Vectorlabs  
Fixing solution     PBST wash buffer   
X1 ddPBS      X1 ddPBS   
4% (w/v) Paraformaldehyde    0.1% (v/v) Tween-20 
pH 7.2, Storage 4°C       
        
Blocking solution 
X1 PBST wash buffer 
10% (w/v) BSA  
Storage 4°C 
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Buffers used for western blotting 
1X 8% Resolving SDS 
Gel: 
 1X 6% Resolving SDS Gel: 
ddH2O 4.6mL ddH2O 5.3mL 
30% acrylamide 2.7mL 30% acrylamide 2.0mL 
1.5Mm Tris (pH 8.8) 2.5mL 1.5Mm Tris pH (8.8) 2.5mL 
10% SDS 0.1mL 10% SDS 0.1mL 
10% Ammonium 
persulphate 
0.1mL 10% Ammonium 
persulphate 
0.1mL 
TEMED 0.006mL TEMED 0.008mL 
 
1X 5% Stacking SDS Gel:  Reducing sample buffer: 
ddH2O 3.4mL 0.5M Tris-HCl (pH 6.8) 
30% acrylamide 0.83mL 2% (w/v) SDS 
1.5Mm Tris pH 6.8 0.63mL 10% (v/v) Glycerol 
10% SDS 0.05mL 1% DTT 
10% Ammonium persulphate 0.5mL  
TEMED 0.005mL  
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Tris buffered saline + Tween-20 (TBST) TBST + Marvel blocking buffer:  
1.21g Tris base 100mL TBST 
22.33g NaCl 10% (w/v) Marvel milk powder 
pH made to 7.5 with HCl  
100mM sodium orthovanadate  
100mM sodium fluoride  
0.05% Tween-20  
 
5X SDS gel running buffer: 
 
SDS gel transfer buffer: 
15.1g Tris-base 5.8g Tris-base 
94 Glycine 2.9g Glycine 
50mL 10% (w/v) SDS 0.37g SDS 
1L ddH2O 200mL Methanol 
Made to 1X for each use in ddH2O 800mL ddH2O 
 
Real time PCR 
Primers 
All oligo-primers were purchased from Eurofins MWG Operon and diluted to a working 
concentration of 10pg/µl using ddH2O and stored at -20°C. 
Reagents and buffers 
- RNA extraction: 
RNA STAT-60                     Amsbio 
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- Reverse transcription: 
M-MLV Reverse Transcriptase and 5X Reaction Buffer           Promega 
Oligo(DT) 15 Primer                     Promega 
RNasin Ribonuclease Inhibitor        Promega 
- PCR setup: 
iQ Sybr Green SuperMix                     BioRad 
100mM dNTP’s          Promega   
 
2.1.1.3 Thymidine incorporation assay materials  
 
[6-
3
H]-Thymidine (
3
Thy), 1mCi (37Mbq)                            Amersham  
96 Uni/Filter scintillin-coated plates                          PerkinElmer  
Microscint-O Scintillation media               Perkin Elmer 
Packard Instrument Co. 96-well plate              Ultima Gold 
 
Wash buffer                 Reagent diluent 
X1 ddPBS                  Storage 4°C, 0.2µm filtered before use 
0.05% (v/v) Tween-20               X1 ddPBS 
            1% (w/v) BSA 
 
2.1.1.4 Cell line transfection 
  
- siRNA transfection: 
siRNA negative control      Eurogentec 
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siRNA CEP290 and T21     Eurogentec 
 
- shRNA transfection: 
shRNA negative control         OriGene Technologies 
shRNA T21       OriGene Technologies 
 
2.1.1.5 Cell lines and growth Conditions: 
All cells were grown as a monolayer in incubators supplying a 37°C, 5% CO2 atmosphere 
Cell Line / 
Source  
Tumour origin and cell line 
features  
Culture media  
DU145 / 
ATCC  
Prostate carcinoma derived 
from brain  
DMEM + 10% FCS, 1% pyruvate  
LNCaP / 
ATCC  
Androgen dependent prostate 
carcinoma derived from 
lymph node  
RPMI 1640 + 10% FCS + 1% L-glutamine  
PC3 / ATCC  Prostate adenocarcinoma 
derived from bone  
HAM-F-12K + 10% FCS  
OPCT-1 and 
clones / 
Onyvax  
Derived from prostate 
tumour epithelium  
KSFM + 2% FCS  
 
Table 2.1. 1  List of cancer cell lines used in this study, describing their origins, features 
and growth conditions. 
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2.2 Methods and procedures: 
2.2.1 Cell lines and Growth Conditions 
2.2.1.1 Cell line freezing 
Cell lines were maintained in a humidified incubator at 37
o
C, 5% CO2. Confluent monolayer 
cells were rinsed and washed three times with an appropriate volume of DPBS to remove 
residual media, and dislodged by using 1X Trypsin/Versene, centrifuged at 400g, 4
o
C for 3 
minutes, counted using trypan blue exclusion method and seeded at the appropriate density into 
cell culture flasks or plates.  
Suspension cell lines were passaged by centrifuging cell suspension and splitting the resuspend 
pellet into flasks, which were replenished with fresh culture media and antibiotics as required.  
All cell lines were frozen to be grown, if required, for further investigations in 1ml cryovials 
using freezing media comprising of 50% FCS, 40% culture media and 10% DMSO. Cells were 
frozen at -80
 o
C for one day prior to transfer into liquid nitrogen for long term storage. 
2.2.2 RNA extraction, transcription and qRT PCR  
2.2.2.1 RNA extraction from cell lines 
RNA was extracted using RNA STAT-60 according to the manufacture’s instructions. Cells 
were homogenised using 500µl per 2x10
6
 cells of RNA STAT-60 in 1.5ml eppendorf tubes and 
left at room temperature for 3 minutes. To this, 100µl of chloroform per 500µl of RNA STAT-
60 was added and mixed by shaking vigorously for 60 seconds and again tubes were left for 3 
minutes at room temperature. Tubes were then centrifuged at 14,000g, 4°C for 15 minutes and 
the colourless upper aqueous phase containing RNA was carefully removed into a fresh 1.5ml 
eppendorf and the phenol red phase discarded. To this, 250µl of isopropanol per 500µl of RNA 
STAT-60 was added and the solution left at room temperature for 8 minutes in order to 
precipitate out RNA before again centrifuging at 12,000g, 4°C for 10 minutes. The supernatant 
was removed and discarded leaving a white pellet, and the RNA washed using 1ml of 75% 
ethanol followed by centrifugation at 7,500g, 4°C for 5 minutes. The supernatant was again 
removed and discarded and the white pellet left to air dry completely until clear. The pellet was 
resuspended in an appropriate volume between 10-30µl of ddH2O and stored at -80°C and used 
within 6 months. RNA concentration was measured using a Nanodrop spectrophotometer and 
resuspended to a concentration of 1µg/µl in ddH2O ready for Reverse Transcription. 
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2.2.2.2 Reverse Transcription 
 
For first-strand cDNA synthesis from RNA was prepared following manufacture’s instructions 
described below per sample. Into a 0.5ml eppendorf, 2µg of RNA, 0.5µg of the Oligo (DT) 15 
primer and ddH2O were added to give a final volume of 15µl. The samples were then heated 
using UNO-Thermoblock to 70°C for 5 minutes to melt secondary structures. Samples were 
then immediately put on ice before the following were added to each sample: 
 M-MLV 5X Reaction Buffer 5.0µl 
 40mM dNTP’s 1.0µl 
 RNasin Ribonuclease Inhibitor 0.7µl 
 M-MLV RT 1.0µl 
 ddH2O 2.3µl 
Samples were mixed gently and incubated for 80 minutes at 39.2°C in a water bath. After 
incubation, samples were finally heated using an UNO-Thermoblock to 95°C for 5 minutes and 
immediately stored at -20°C ready for qRT PCR. 
2.2.2.3 Quantitative Real Time PCR (qRT-PCR) 
 
qRT-PCR was set up into PCR tubes using Sybr Green SuperMix following manufacture’s 
instructions described below per sample. In cases of Non-Template Controls (NTC), cDNA 
template was substituted with ddH2O.  
 Sybr Green 6.25µl 
 ddH2O 4.75µl 
 5’ end primer 0.5µl 
 3’ end primer 0.5µl 
 cDNA template 0.5µl 
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Samples were run on a qRT-PCR Thermal Cycler. Samples were run in duplicate and repeated 
at least 3 times to ensure validity of results which were then analysed using ΔCt equation. 
Gene Primer Sequence (5’-> 3’) Tm [°C] 
Centrosomal 
Protein 
(CEP290) 
CEP290 new F 5’-CGTCAAGAAGAACTGGCAGA-3’ 61 
CEP290 new R 5’-GCTCATTTACTTCCACCTTGG-3’ 
T21 unique 
region 
T21 qPCR F 5’-CAAAGAATGAAATCATAGCACAGG-3’ 55 
T21 qPCR R 5’-TTCTGTTCTGCCTGGCTTCT-3’ 
HKG: TBP-1 
 
TBP-1 F 5’-TGCACAAGGAGCCAAGAGTGAA-3’ 57 
TBP-1 R 5’-CACATCACAGCTCCCCACCA-3’ 
HKG: HPRT-1 HPRT-1 F 5’- TGACACTGGCAAAACAATGC-3’ 57 
HPRT-1 R 5’-GGTCCTTTTCACCAGCAAGCT-3’ 
Table 2.2. 1  Primer summary table showing primer sequences and optimal annealing 
temperatures when using Real Time qPCR Thermal Cycler. 
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(A)  
Primer Sequence (5’-> 3’) Tm [°C] 
CHD8 F: CACTGACTGCTTTCGGGTGGAA 
R: GGTCTCCACATCTCGTTCAGTC 
63 
 
TP53INP2 F: TTCGTGTCGGAGGAGGATGAAG 
R: AACCAGCTCTCGTCCATCAAGG 
 
63 
DUSP14 F: GTAGGCTTCTGGAGGCAACTGA 
R: ATCAGGTGTCGGGACTCCTTCT 
 
63 
IGFBP5 F: CGTGCTGTGTACCTGCCCAATT 
R: ACTTGTCCACGCACCAGCAGAT 
63 
 
ZBTB7A F: GCAACATCTGCAAGGTCCGCTT 
R: TCTTCAGGTCGTAGTTGTGGGC 
63 
 
FRS3 F: CTATGGCTACGACTCCAACCTC 
R: GCACTGCATCAGATCCTGAAGG 
63 
 
RAB6B F: CAACAAGACGGACCTGGCTGAT 
R: CGTTGTAGCCAGTCTTCGCACT 
63 
 
FGF1 F: ATGGCACAGTGGATGGGACAAG 
R: TAAAAGCCCGTCGGTGTCCATG 
63 
 
PDZD2 F: AGTGACTGTCGCTGGCTTTCAG 
R: GACAGAGCACTGGCTAGTTCAC 
63 
 
BCL2L12 F: AGACCGCAAGTTGAGTGGAGGA 
R: AGCCTCACCACGCCTAAGGAAG 
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(B) 
Primer Sequence (5’-> 3’) Tm [°C] 
MAPK6 F: GACATGACTGAGCCACACAAACC 
R: GATGGGAGAGTGCTTCTTCTGC 
63 
CALM3 F: GAGAGGCGTTCCGTGTCTTTGA 
R: ACCTCCTCATCGGTCAGCTTCT 
63 
HIPK2 F: AGCGTCATCACCATCAGCAGTG 
R: AGTCGTGGACTGTGACACAGCT 
63 
RAP2A F: TCTACAGCCTCGTCAACCAGCA 
R: TCTGCCTTCGCTGGACGATACT 
63 
BCL10 F: CACCCTTGTTGAATCTATTCGGC 
R: GAGGTTGTTCGTGGCTCCATCT 
61 
MAP2K F: GGTGTTCAAGGTCTCCCACAAG 
R: CCACGATGTACGGAGAGTTGCA 
63 
TP53BP2 F: AGCACTGGGAATGCTCTGGATC 
R: GGCATTGGACTGGTCTACTGCA 
63 
CDK6 F: GGATAAAGTTCCAGAGCCTGGAG 
R: GCGATGCACTACTCGGTGTGAA 
63 
NDFIP2 F: GTGATGCAGACCAGCTCAGAGT 
R: CGCAGATAGCACCATACCTTCC 
63 
CEP290 F: GCTTCGATTGCCTGCCACTGC 
R: GCAGTGGCAGGCAATCGAAGC 
62 
 
Table 2.2. 2 List of primers used for NGS data validation by qRT-PCR. 
 (A) Primers were used for up regulated gene validation and (B) Primers for down regulated 
genes. 
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2.2.2.4 Statistical Analysis 
 
For various experiments performed in this study, statistical analysis was carried out to 
highlight their significance. In the first instance, on studies where biological repeats were 
performed, the difference between repeats was determined using standard deviation, 
calculated from average values obtained for the control or test measures used in each 
experiment. In certain cases, the significance between values gained was examined. On these 
occasions, the p value was calculated using a student’s t test, which would allow the 
recognition of differences that were significant (‘*’/p=<0.05), very significant 
(‘**’/p=<0.01), highly significant (‘***’/p=<0.001) or very highly significant 
(‘***’/p=<0.0001). 
 
2.2.3 Immunofluorescence staining 
2.2.3.1 Cell preparation 
 
A day prior to immunofluorescent staining, cells were dispensed into a 24 well flat bottom 
plate at a concentration of 1x10
5
cells/ml at 1ml per well each containing one sterile round 
glass cover slip. The cells were then incubated overnight at 37°C, 5% CO2 so that cells would 
be between 85-95% confluent at the time of staining.  
2.2.3.2 Immunofluorescence staining 
 
The following day, media was removed from the wells and 200µl of cold 4% 
paraformaldehyde solution was added to each well for 15 minutes at 4°C in order to fix cells.  
Wells were then washed once for 10 minutes using ddPBS whilst on a plate rocker. Wells 
were then blocked for 60 minutes using blocking buffer. Following blocking, primary 
antibodies and IgG isotype controls were prepared in blocking buffer at optimal dilutions as 
suggested by manufacture’s instructions and added to appropriate wells and left to incubate at 
room temperature on a plate rocker. After 60 minutes, the wells were washed using wash 
buffer x3 times for 10 minutes and the secondary antibodies prepared using blocking buffer 
and added to appropriate wells. Plates were then wrapped in foil and incubated at room 
temperature whilst rocking for 60 minutes. Following washing with wash buffer as before 
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round glass cover slips were removed from the base of the wells and placed cell side down 
onto mounting fluid containing DAPI on microscope slides. Slides were placed in slide 
holders and wrapped in foil and kept at 4°C until ready to view using a fluorescence 
microscope.  
2.2.4 Western Blotting 
 
For immunoblotting, DU145, PC3 and LNCaP prostate cancer cell lines were collected, 
washed with 1X PBS, lysed in 1X solution containing 50mM Tris-HCl (pH 6.8), 100mM 
dithiothreitol, 2% (w/v) SDS, 0.1% (w/v) bromophenol blue, and 10% (v/v) glycerol, and 
loaded on Tris/glycine SDS-polyacrylamide gels. SDS gels were prepared according to 
recipes shown in materials description. This was topped with a propanol organic solvent layer 
to inhibit bubble formation and allowed to set. Once the resolving gel had set the organic 
solvent layer was removed and replaced with a gel comb. The stacking gel solution is then 
added around the comb filling the gel mould. When the stacking gel had polymerised the 
comb was removed to reveal the gel channels (wells). Following denaturisation the gel 
moulds were placed into the electrophoresis tank and were filled with x1 running buffer, to 
the far left well 4 μL of protein standard ladder was added (Bio-Rad Western C precision 
plus™ protein standards). Once the samples were loaded, the gels were run at 100V until the 
dye front reached the bottom of the stacking gel, approximately 30-40 minutes, the voltage 
was then increased to 150V until the dye front reached 1cm from the bottom of the gel, 
approximately 1 hour. 
 Protein bands were transferred onto Amersham Hybond-P PVDF membranes (GE 
Healthcare). Membranes were blocked with 10% Marvel milk/Tris buffered saline (TBS) 
solution with 0.05% Tween-20 (TBST) containing sodium orthovanadate and sodium 
fluoride at 100V for 1 hour. Following TBST washes 3x 10 minutes each, membranes were 
incubated with primary antibodies (in blocking solution) at 4ºC for overnight. Then, the 
membranes were washed with TBST solution before adding the secondary antibodies and 
incubated for 1 hour at room temperature. Visualisation of bands was performed with Rapid 
Step ECL reagent (Calbiochem) and viewed using a CCD camera (Fujifilm). 
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2.2.4.1 Total Protein Assay 
 
To calculate cell lysate protein concentration, total protein assay were performed using 
BioRad Dc protein assay reagents according to the manufacturer’s protocol. Standards were 
diluted from a stock BSA solution (10mg/ml) to create a series of standard dilutions (2, 1.5, 
1.0, 0.8, 0.5, 0.4, 0.2 and 0mg/ml). Standards were tested in duplicate, while protein extracts 
were tested in triplicate. All assays were carried out in 96-well round bottom plates. 25µl of 
reagent A was applied to all samples followed by 200µl reagent B. Plates were covered in foil 
and left to incubate for one hour at RT. Absorbance measurements for plates were read using 
a plate reader set to a 750nm wavelength. Using these absorbance values, protein fraction 
concentrations were calculated. 
2.2.5 siRNA (Small Interfering RNA) knockdown  
 
Transfection of OPCT-1, PC3 and DU145 using CEP290 siRNAs was done using 
INTERFERin transfection reagent according to the manufacturer’s protocol. Briefly a day 
prior to transfection, cells were dispensed into a 24 well flat bottom plate at a concentration 
of 5x10
4
 cells/ml and left to incubated overnight at 37°C, 5% CO2 so that cells would be 
between 30-50% confluent at the time of transfection. 
The following day, siRNA stocks were prepared at 40µM/well in 100µl/well of serum free 
OPTIMEM media and mixed. To these mixtures 2µl/well of INTERFERin reagent was added 
and vortexed for 10 seconds. Further controls of INTERFERin only and OPTIMEM media 
alone were prepared and all mixtures were incubated at room temperature for 10 minutes to 
allow complexes to form. These complexes were then added drop wise whilst on a rocking 
platform at a volume of 100µl/well to appropriate cells containing 100µl/well of complete 
media. All plates were left to rock for 10 minutes before incubating at 37°C, 5% CO2 for 6 
hours after which 500µl of pre-warmed complete media was added to each well and 
incubated.   
2.2.6 Proliferation assay 
2.2.6.1 Proliferation assays preparation 
 
Transfected cell lines were harvested and centrifuged at 400g, 4°C for 3 minutes resuspended 
their growth media and counted using trypan blue. Cell concentration was adjusted to 5x10
4
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cells/100µl per well using appropriate media and dispensed into appropriate wells of a 24 
well plate.  
2.2.6.2 Post transfection procedure 
 
Cultures were incubated for between 24-48 hours at 37°C, 5% CO2, and [
3
H]-Thymidine was 
added at 37 MBq/well in the last 18 hours of incubation. Following incubation, the media 
were then removed and the cells were washed with 100µl of ddH2O and scrubbed to be 
transferred into a 96-well round bottom plate. An additional 100µl of ddH2O was added to 
wash out residual cells in the wells giving a final volume of 200µl/well. Plates were then 
harvested using a cell harvester onto 96 Uni/Filter scintillation plates and were counted using 
a Top-Count counter. Results are expressed in counts per minutes (cpm) and as a means of 
the quadruplicate wells.  
2.2.7 shRNA (short hairpin RNA) transfection 
2.2.7.1 shRNA (short hairpin RNA) transfection 
 
Stable transfection of cell lines using a pGFP-B-RS vector with blasticidin resistance gene 
and containing T21 shRNA designed as follows: (sense:5’GCACAGGAATTCTTGATCA3’ 
TCAAGAG - antisense:5’TGATCAAGAATTCCTGTGC3') (purchased from Origene 
Technologies) was performed using Lipofectamine-2000 transfection reagent according to 
the manufacturers protocol (Performed by Dr Amanda Miles). A day prior to transfection, 
cells were cultured into a 24 well flat bottom plate at a concentration of  5x105 cells/ml and 
left to be incubated overnight at 37°C, CO2 so that cells would be between 85-95% confluent 
at the time of transfection. 
The following day, shRNA stock was prepared in HAM-F-12K media at a concentration of 
1.2µg/50µl per well and mixed gently. Alongside to this, 2µg/50µl per well of Lipofectamine 
2000 was prepared and both preparations were left to incubate at room temperature for 5 
minutes before combining the diluted DNA and Lipofectamine 2000 allowing complexes to 
form at room temperature for 30 minutes. During which, media from the wells of the 
overnight cultures were removed and replaced with 100µl of the complexes containing the 
DNA/Lipofectamine solutions which were added dropwise to the wells whilst on a rocking 
platform and then incubated at 37°C, 5% CO2 for 6 hours, after which a further 900µl of pre-
warmed HAM-F-12K media was added and left to incubate. Following 48hrs of transfection, 
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media from the wells was removed and fresh media containing 25µg/ml of Blasticidin 
selective antibiotic and observed over the following days. 
2.2.7.2 Clonal selection and Cell Sorting: 
 
Following 3-4 days post-transfection, cells were trypsinised and removed from wells and 
centrifuged at 400 g, RT for 3 minutes and resuspended in complete culture media. The cells 
were counted using trypan blue exclusion method and seeded into 96-well flat bottom plates 
at concentrations of 10 cells, 1 cell and 0.33 cells/well with the addition of 25 μg/ml 
blasticidin. Plates were observed over the following weeks and growing clones tested for T21 
gene expression using qRT-PCR and immunofluorescent staining over several passages to 
ensure stable transfection.  
Following culture of clones positively expressing GFP post-transfection, cells were 
trypsinised and removed from wells and centrifuged at 400 g, RT for 3 minutes and 
resuspended in culture media. Cells then underwent cell sorting using a MoFlo XDP High-
Speed Cell Sorter under sterile conditions to enable re-culture of GFP positive cells. 
Following sorting, cells were gently centrifuged 300 g, RT for 3 minutes and seeded into 
flasks. Cells were supplemented with antibiotics 2 days post-cell sorting. 
2.2.8 Investigation into T21 knockdown on cell signaling 
2.2.8.1 Proteome Profiler Arrays 
 
Mitogen activated protein kinase (MAPK) Proteome Profiler kits were obtained from R&D 
systems. These were used in conjunction with T21-stable shRNA transfectant lines. These 
kits were used as according to the manufacturer’s protocol. Prior to testing, protein 
concentration of cells was assessed under manufacturer’s advice and performed using the 
total protein assay protocol described in 2.2.4.1. After secondary antibody application, arrays 
were washed as stated in the protocol. ECL reagents were used to lightly wash each 
membrane and they were developed using the same technique as for immune blots described 
in 2.2.4.  Following this, membranes were placed into a CCD camera chamber cooled to -
25oC for development prior to the image being captured. Spot densitometry to test intensity 
was performed using ImageJ software. 
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3 CHAPTER THREE: Characterisation of T21 and CEP290 at the 
molecular level and protein expression 
3.1 Introduction 
 
Since T21 (testis clone 21) has been identified to be a potential target antigen for 
immunotherapy, it has been considered for further investigations to approve its reliability as 
an effective tumour biomarker. The consecutive investigations of T21 have been substantially 
utilised in prostate cancer, focusing on the current understanding of its observed gene 
sequence similarities with a centrosomal protein called CEP290. Furthermore, T21 has 
required additional validations in terms of molecular characterisation and its functional 
attributes and, subsequently, determining its possible role in cancer. The preceding studies on 
T21 as a novel prostate cancer antigen were reported in previous publication (Miles et al., 
2007; Miles et al., 2012). 
T21 was first identified in 2007 by Miles et al as member of the Tumour Associated 
Antigens’ family (TAAs) using a modified SEREX screening of cDNA libraries that were 
constructed from normal human testicular mRNA, expressed in plasmids and probed with 
allogeneic sera from prostate cancer patients (Miles et al., 2007 ) (Figure 3.1.1).  
 
Figure 3.1. 1 Modified SEREX approach used to identify T21.  
A normal testicular cDNA library was screened with allogeneic sera from prostate cancer 
patienst, from which positive clones were isolated and analysed. 
 
In brief, an allogeneic testicular cDNA expression library (purchased from Clontech, USA) 
was screened using pooled prostate cancer patients’ serum; pooled sera from four patients 
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having prostate cancer were used for screening. The reactive clones were isolated and 
subjected to two further rounds of screening in order to enhance their monoclonality. Which 
was then excised in vivo and subsequent restriction mapping and sequencing of the clones 
were performed on the cDNA. Further molecular analyses were subsequently performed to 
investigate its potential as an immunotherapeutic antigen. Therefore, PCR experiments were 
performed using testicular cDNA with the amplified T21 cloned sequence. In 2001, In silico 
analysis revealed the location of the T21 DNA sequence on chromosome 12q21.33 and 
further sequence analysis showed the full nucleotide sequence to be 2797bp in length, 
encoding a novel 524 amino acid protein. Structurally, T21 was found to consist of 19 exons 
with 12 exons covering the coding region of the gene. Expression analysis studies, using both 
conventional and qRT-PCR demonstrated the aberrant expression of T21 mRNA in various 
human neoplasms including gastric, kidney, and prostate cancer tissues and cell lines. Mild 
expression in benign prostatic hyperplasia (BPH) was observed for T21 but low or no 
expression was observed in other normal tissues examined (Miles et al., 2007). 
Further investigations on T21 focused on determining the expression of T21 mRNA and 
protein in cell lines and in healthy, benign and cancerous tissues (Dr Alistair Rogers, MD 
Thesis 2009). The findings supported the hypothesis that T21 could be defined as a cancer-
testis antigen due to the restricted expression profile in a number of malignancies and testis 
and the ability of T21 to induce an immune response in the tumour bearing host. 
Furthermore, T21 appeared to show increased expression according to tumour grade and 
stage and its role in cell proliferation suggest its relevance to prostate cancer development 
(Miles et al., 2012). The project also revealed homology between T21 and CEP290. 
CEP290, also named cancer/testis antigen 87 (CT87), and CTCL tumor antigen se2-2, 
monoclonal antibody 3H11 antigen, is a 93.2kb gene located on chromosome 12q21.32; it 
spans 54 exons and forms a large protein product with a predicted molecular weight of 
290kDa (Nagase et al., 1997). It was first identified from proteomic screening of a human 
lymphoblast cell line. Although the exact role of CEP290 protein is still largely unknown, it 
has been shown to play a role in centrosome organisation and basal bodies, cilia function and 
has been shown to associate with microtubule-based transport proteins including centrin, 
gamma-tubulin, Kinesin-like protein KIF3A, ninein and pericentrin (Chang et al., 2006). It 
has also been shown to interact with PCM1 a trafficker of centrosomal proteins,linked with 
the maintenance of spindle pole integrity maintenance prior to and during cell mitosis 
(Coppieters et al., 2010).  
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In 1997, Nagase and colleagues identified from human brain cDNA library sequences, 
KIAA0373 as a partial homologue of CEP290 (Nagase et al., 1997). Later, in 2001, another 
partial homolog of CEP290 was found expressed in a gastric cancer cell line library and 
termed 3H11Ag. This Ag was determined using monoclonal antibody (MAb) 3H11 which 
can bind specifically to different cancer cells obtained from different tissues. The nucleotide 
sequence analysis of the cDNA frame of 3H11 indicated that there was no highly 
homologous gene in the GenBank library. They identified a transcript of approximately 2.3kb 
in size and a 70 kDa encoded- protein from the generated sequence obtained (Chen and Shou, 
2001). Subsequently, Andersen and colleagues in 2003 carried out proteomic investigations 
of the centrosomal fractions of CEP290 during interphase (G1/S phase) in human 
lymphoblastic KE37 cells. 
Furthermore, there are more than 100 mutations associated with the CEP290 gene that have 
been identified mainly as cilia related disorders such as Joubert syndrome, Senior-Loken 
syndrome (Sayer et al., 2006; Valente et al., 2006), Leber congenital amaurosis (den 
Hollander et al., 2006), and Bardet-Biedl syndrome (Leitch et al., 2008). Although the role of 
CEP290 in cancer in unknown, homologues of CEP290 have been found in some forms of 
cancers such as CTCL tumour antigen SE2-2 / AF273044.1 which were identified as a 
tumour antigen in leukaemia and melanoma cell lines and, also 3H11 (mentioned above) in 
gastric cancer cell lines (Eichmuller et al., 2001; Chen & Shou, 2001). 
 
The main objectives of this part of the project were: 
1- To investigate the expressions levels of T21 and CEP290 mRNA and protein in cancer cell 
lines. 
2- To investigate the effect of CEP290 knockdown on T21 mRNA expression. 
3- To investigate the effect of CEP290 and T21 knockdown on cell proliferation.  
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3.2 Results: 
3.2.1 T21 and CEP290 mRNAs and protein expression in cancer cell lines: 
 
Previous findings demonstrated sequence similarities between T21 and CEP290 transcripts. 
Therefore, it was crucial to investigate the differences between the two molecules at the 
mRNA and protein levels.  Quantitative RT-PCR has been used to investigate the expression 
of CEP120 and T21 at the mRNA level. Immunofluorescence and immunoblotting were used 
to investigate their expression at the protein level. 
In order to compare the expression of T21 and CEP290 expression at the mRNA level, a 
more sensitive approach was adopted to quantify mRNA using quantitative real time 
quantitative PCR. Primers designed within the unique region were used to specifically 
amplify T21. They were optimised to achieve maximal efficiency and the relative abundance 
value of specific gene expression was determined by dividing the value derived by that of 
averaged housekeeping genes (Pfaffl, 2001). Two different housekeeping genes were used in 
this experiment, hypoxanthine guanine phosphoribosyl transferase 1 (HPRT-1) and TATA-
box binding protein (TBP), as they both displayed low variability across samples and were 
therefore used for calculating relative gene expressions in all subsequent analyses. 
Quantitative RT-PCR experiments were performed following extraction of mRNA from a 
panel of cell lines derived from melanoma, breast and head and neck cancers. Here, to avoid 
DNA contamination (and possible amplification of intronic CEP290) of the mRNA, RNA 
spin columns were used instead of routine acid guanidinium thiocyanate-phenol-chloroform 
extraction using STAT-60. 
CEP290 primers were designed within the upstream untranslated 5’ prime region of T21 up 
to and including the unique region. In light of the genomic alignment to CEP290, it was clear 
that the verification of the 3’ and 5’ end sequences of T21 would allow for a more complete 
transcriptional interpretation (Dr Amanda Miles, PhD Thesis 2004). The presence of the 
unique stop codon was confirmed by PCR with forward primers designed within the unique 
region and reverse primers designed to include the unique stop sequence codon. (Dr Suman 
Malhi, PhD Thesis 2013) (Figure 3.2.1.1) 
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(CEP290):ATTTGAAGTCCTCGTTCCACGCCTTCTCATCATCCTGAACACCGAGCTC
TGGGACTCCGGCGGAGAATCTAAACGTAAAGCATCACCCACGGTCGTGAACTGT
AGGCTCTCCTGGCATCCGGGATCTTATTCTGGCCTTGGCGGAGTTGGGGATGGTG
TCGCCTAGCAGCCGCTGCCGCTTTGGCTTGCTCGGGACCATTTGGCTGGACCCAG
AGTCCGCGTGGAACCGCGATAGGGATCTGTCAGGGCCCGCGGCCGGGTCCAGCT
TGGTGGTTGCGGTAGTGAGAGGCCTCCGCTGGTTGCCAGGCTTGGTCTAGAGGTG
GAGCACAGTGAAAGAATTCAAGATGCCACCTAATATAAACTGGAAAGAAATAAT
GAAAGTTGACCCAGATGACCTGCCC(CEP290_primer_F)CGTCAAGAAGAACTG
GCAGATAATTTATTGATTTCCTTATCCAAGGTGGAAGTAAATGAGC(CEP290_pr
imer_R)TAAAAAGTGAAAAGCAAGAAAATGTGATACACCTTTTCAGAATTACTCA
GTCACTAATGAAGATGAAAGCTCAAGAAGTGGAGCTGGCTTTGGAAGAAGTAGA
AAAAGCTGGAGAAGAACAAGCAAAATTTGAAAATCAATTAAAAACTAAAGTAAT
GAAACTGGAAAATGAACTGGAGATGGCTCAGCAGTCTGCAGGTGGACGAGATAC
TCGGTTTTTACGTAATGAAATTTGCCAACTTGAAAAACAATTAGAACAAAAAGAT
AGAGAATTGGAGGACATGGAAAAGGAGTTGGAGAAAGAGAAGAAAGTTAATGA
GCAATTGGCTCTTCGAAATGAGGAGGCAGAAAATGAAAACAGCAAATTAAGAA
GAGAGAACAAACGTCTAAAGAAAAAGAATGAACAACTTTGTCAGGATATTATTG
ACTACCAGAAACAAATAGATTCACAGAAAGAAACACTTTTATCAAGAAGAGGGG
AAGACAGTGACTACCGATCACAGTTGTCTAAAAAAAACTATGAGCTTATCCAAT
ATCTTGATGAAATTCAGACTTTAACAGAAGCTAATGAGAAAATTGAAGTTCAGA
ATCAAGAAATGAGAAAAAATTTAGAAGAGTCTGTACAGGAAATGGAGAAGATG
ACTGATGAATATAATAGAATGAAAGCTATTGTGCATCAGACAGATAATGTAATA
GATCAGTTAAAAAAAGAAAACGATCATTATCAACTTCAAGTGCAGGAGCTTACA
GATCTTCTGAAATCAAAAAATGAAGAAGATGATCCAATTATGGTAGCTGTCAAT
GCAAAAGTAGAAGAATGGAAGCTAATTTTGTCTTCTAAAGATGATGAAATTATTG
AGTATCAGCAAATGTTACATAACCTAAGGGAGAAACTTAAGAATGCTCAGCTTG
ATGCTGATAAAAGTAATGTTATGGCTCTACAGCAGGGTATACAGGAACGAGACA
GTCAAATTAAGATGCTCACCGAACAAGTAGAACAATATACAAAAGAAATGGAAA
AGAATACTTGTATTATTGAAGATTTGAAAAATGAGCTCCAAAGAAACAAAGGTG
CTTCAACCCTTTCTCAACAGACTCATATGAAAATTCAGTCAACGTTAGACATTTT
AAAAGAGAAAACTAAAGAGGCTGAGAGAACAGCTGAACTGGCTGAGGCTGATG
CTAGGGAAAAGGATAAAGAATTAGTTGAGGCTCTGAAGAGGTTAAAAGATTATG
AATCGGGAGTATATGGTTTAGAAGATGCTGTCGTTGAAATAAAGAATTGTAAAA
ACCAAATTAAAATAAGAGATCGAGAGATTGAAATATTAACAAAGGAAATCAATA
AACTTGAATTGAAGATCAGTGATTTCCTTGATGAAAATGAGGCACTTAGAGAGC
GTGTGGGCCTTGAACCAAAGACAATGATTGATTTAACTGAATTTAGAAATAGCA
AACACTTAAAACAGCAGCAGTACAGAGCTGAAAACCAGATTCTTTTGAAAGAGA
TTGAAAGTCTAGAGGAAGAACGACTTGATCTGAAAAAAAAAATTCGTCAAATGG
CTCAAGAAAGAGGAAAAAGAAGTGCAACTTCAGGATTAACCACTGAGGACCTGA
ACCTAACTGAAAACATTTCTCAAGGAGATAGAATAAGTGAAAGAAAATTGGATT
TATTGAGCCTCAAAAAT(T21):ATGAGTGAAGCACAAT(T21_primer_F)CAAAGAA
TGAAATCATAGCACAGGAATTCTTGATCAAAGAAGCAGAGTGTAGAAATGCAG
ATATAGAGCTTGAACATCACAGAAGCCAGGCAGAACAGAA(T21_primer_R)TGA
ATTTCTTTCAAGAGAAC…… 
Figure 3.2.1. 1 Genomic sequence of the new designed primers used for CEP290 and 
T21.  
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Subsequently, further investigations into T21 as a biomarker of prostate cancer could be 
aided by analysing mRNA and protein expression profiles in comparison to CEP290 in order 
to elucidate its function and involvement, if any, in cancer. In summary, the discovery of the 
unique T21 sequence and its translation into protein holds the possibility of a potential 
prostate cancer biomarker and further study as to its immunogenicity could present a viable 
immunotherapeutic target and may suggest its incorporation into a cancer vaccine. 
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Figure 3.2.1. 2 qRT-PCR for T21 and CEP290 mRNA expression in human cancer cell 
lines.  
Real time PCR expression of CEP290 and T21 mRNAs in various cancer cell lines derived 
from breast, melanoma and head and neck origin. Experiment was carried out three times in 
duplicate (n=3) represented with standard error of mean with data calculated by ΔCt and 
represented as relative gene expression. 
 
T21 and CEP290 mRNAs expressions were detected in most of cancer cell lines assessed, 
T21 expression was remarkably higher in breast (MDA-P3 and MCF-7), metastatic 
66 
 
melanoma (MM30) and head and neck cancer cell line (A253) (Figure 3.2.1.2). In the 
prostate cancer cell lines DU145, PC3 and LNCaP (all derived from disseminated tumour 
cells at metastatic secondary sites), CEP290 expression was higher than T21. In addition, T21 
expression was lower in LNCaP, OPCT-1 clone (T21high/CD44high) and OPCT-2 (Figure 
3.2.1.3). 
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Figure 3.2.1. 3 qRT-PCR for T21 and CEP290 mRNAs expression in prostate cancer 
cell lines.  
Experiment was performed three times in duplicate (n=3) represented with standard error of 
mean with data calculated by ΔCt and represented as relative gene expression. 
 
To compare the expression of T21 and CEP290 at the protein level, , immunofluorescent 
staining using prostate cancer cell lines (PC3, DU145, OPCT-1 parental) were performed 
with polyclonal antibodies against T21 and CEP290 (Figure 3.2.1.2). Although fluorescent 
immunostaining of T21 and CEP290 showed a cytoplasmic co-localisation of the two 
proteins, this raised a question about the specificity of T21 antibody. Consequently, it was 
essential to use an antibody that recognizes specifically the unique-region of T21. This 
antibody (Pacific Immunology, USA) was designed and optimised to differentiate between 
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T21 and CEP290 expression using fluorescent immunostaining and Western blotting. T21 
was expressed in the cytoplasm of DU145, PC3 and LNCAP cells as tested by 
immunofluorescence staining. In the LNCaP cell line, T21 was also expressed in the 
membrane, which opens up the possibility to target T21 by using antibody based on 
immunotherapy (Figure 3.2.1.4). The specificity of this antibody was also tested by 
immunoblotting, where it recognised a unique band of approximately 55kDa when using 
LNCaP cell lysates and a prominent band at 57kDa in PC3 and DU145 lysates. Interestingly, 
immunoblotting of these cell extracts using antibody against CEP290 showed a different 
expression pattern, confirming further the specificity of the new T21 antibody (Figure 
3.2.1.6). 
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Figure 3.2.1. 4 Fluorescent immunostaining composites comparing T21poly and 
CEP290 antibodies localisation in prostate cancer cell lines (PC3, DU145, OPCT-1 
parental and OPCT-1 clones).  
Cells were stained with CEP290 antibody (red) and T21poly antibody (green) and nuclear 
staining achieved using DAPI (blue). Centrosomal localisation was observed using CEP290 
was antibody similar to expression when using T21poly antibody. Representative images 
using objective magnification x10 & x20 (n=3). 
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Figure 3.2.1. 5  Immunofluorescence composites comparing T21and CEP290 expression 
in prostate cancer cell lines (LNCaP, PC3 and DU145 cell lines) using T21 unique 
region-specific antibody and CEP290 antibody. 
 Cells were stained with CEP290 antibody (red) and T21unique antibody (green). The nuclei 
were stained with DAPI (blue). Centrosomal localisations were observed using CEP290 
antibody and were absent when using T21unique antibody. Representative images using 
objective magnification x20 (n=3). 
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Figure 3.2.1. 6  Western blot analysis using T21unique and CEP290 antibodies.   
Immunoblotting protein expression in prostate cancer cell lines (LNCaP, PC3 and DU145). 
Protein expression of these prostate derived cell lines showing several discreet bands (57 
kDa for T21unique antibody and 90 kDa for CEP290 antibody ) performed using western 
blotting and using β-actin (45 kDa) as representative protein loading control (n=2). (A 
different antibody with 290kDa for CEP290 is currently used “ongoing work”) 
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3.2.2 Effect of transient gene silencing of CEP290 on T21 expression 
 
PC3 and DU145 prostate cancer cell lines express high levels of CEP290 and T21 mRNAs 
(Figure 3.2.1.3). Therefore, these cell lines were used to investigate the effect of CEP290 
knockdown on T21 expression. Three siRNA oligonucleotides were designed at 5’ sequences 
of CEP290, synthesised and transfected together with the control siRNA into PC3 and 
DU145 using Interferin, a non-liposomal amphiphile transfection reagent. 
Total RNA was extracted from the cells after 24, 48 and 72 hours post transfection using 
RNA spin columns. The total level of CEP290 and T21 mRNAs were assessed by qRT-PCR 
using CEP290 and T21 specific primers (Figure 3.2.2.1 and 3.2.2.2 (As). CEP290 siRNA1 
was the most effective in silencing CEP290 in PC3 (78% inhibition) after 24 hours while the 
remaining two siRNA molecules (siRNA1 and siRNA2) achieved 61% and 58% knockdown 
efficiency, respectively (Figure 3.2.2.1 (C)). In DU145, CEP290 siRNA1 was also the most 
effective in silencing CEP290 with 72% after 24 hours while the other two (siRNA1 and 
siRNA2) produced 62% and 59% knockdown efficiency (Figure 3.2.2.2 (C)). However, the 
transient gene silencing of CEP290 using siRNA1 and 2 has no significant knockdown of 
T21 expression at 24, 48 and 72 hours. However, siRNA 3 did affect T21 expression in PC3 
cells over 24, 48 hours (Figure 3.2.2.1). For DU145 cells siginificant silencing of CEP290 
was achieved 24 hours post transfection for all siRNAs, but siRNA 3 was not specific for 
CEP290; and also demonstrated the ability to silence T21 at 24 and 48 hours (Figure 3.2.2.2) 
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Figure 3.2.2. 1 CEP290 silencing of PC3 (CEP290 and T21 positive expression prostate 
cancer cell line) following CEP290 specific siRNA transfection.  
(A) Time course performed by real time PCR showing CEP290 siRNA1, siRNA2, and siRNA3 
silencing over time 24, 48 and 72 hours. (B) Real time PCR analysis showing the relative 
expression of T21 in PC3 mRNA knockdown following transfection with CEP290 siRNA1, 
siRNA2, and siRNA3 silencing over time 24, 48 and 72 hours. (C) Time course performed by 
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real time PCR showing the percentage of the obtained relative expression of CEP290 post 
CEP290 siRNA1 silencing over time. Experiments were carried out three times in duplicate 
(n=3) represented with standard error of mean with data expressed as percentage change to 
the negative siRNA control. Statistical significance (*p<0.05) (**p<0.01) (***p<0.001) 
(****p<0.0001) as determined by student’s t test. 
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Figure 3.2.2. 2 CEP290 and T21 knockdown of a strong CEP290 and T21 genes 
expression prostate cancer cell line (DU145) following CEP290 specific siRNA 
transfection.  
(A) Time course performed by real time PCR showing CEP290 siRNA1, siRNA2, and siRNA3 
silencing over time 24, 48 and 72 hours on DU145 cells. (B) Real time PCR analysis of T21 
mRNA relative expression following transfection of DU145 cell line with CEP290 siRNA1, 
siRNA2, and siRNA3 silencing over time 24, 48 and 72 hours. (C) Time course performed by 
real time PCR showing the effect (in percentage) of CEP290 siRNA1 silencing over time on 
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DU145 cells. Experiments were carried out three times in duplicate (n=3) represented with 
standard error of mean with data expressed as percentage change to the negative control 
siRNA. Statistical significance (*p<0.05) (**p<0.01) (***p<0.001) (****p<0.0001) as 
determined by student’s t test. 
 
In conclusion, it is shown that gene silencing of CEP290 appears to be specific and its 
expression is independent of T21.  
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3.2.3 Effect of CEP290 knockdown on cellular proliferation 
 
The previous findings reported T21 as prostate cancer antigen which belongs to cancer-testis 
antigens (CTAs) family with highly restricted expression patterns in testis tissue and various 
malignancies, but not in other normal tissues. T21 mRNA also over-expressed in prostate 
cancer compared with benign glands and increased T21 expression was positively correlated 
with pathological stage of disease (Miles et al., 2007; Miles et al., 2012). Moreover, based on 
the in silico analysis T21 has a close association with part of CEP290. To determine whether 
CEP290 and T21 share functional characteristics and to give an insight into their relationship 
and T21 in cancer progression, cell proliferation was assessed following CEP290 gene 
silencing. 
CEP290 is known as nephrocystin 6 and is active in centrosomes and the connecting cilium 
of photoreceptors. Although the functional roles of CEP290 domains in the molecular 
physiology of CEP290 are largely unknown, although the BPNLS domain has been shown to 
permit the partial localisation of CEP290 to the nucleus, where it interacts and modulates the 
activity of Activating Transcription Factor 4 (ATF4) (Sayer et al., 2006). Furthermore, a C-
terminal myosin-tail homology domain may provide a fundamental structural base for the 
myosin motor and could promote the microtubule-associated transport of CEP290 to 
centrosomes (Chang et al., 2006). CEP290 also interacts with a major component of 
centriolar satellites (pericentriolar material 1 (PCM1)), and the cilia regulator centrosomal 
protein 110 (CP110). CEP290 knockdown leads to disruption of the subcellular distribution 
of PCM1 and protein complex formation with PCM1 and is associated with disorganisation 
of the cytoplasmic microtubule network. This suggested that CEP290 is required for 
ciliogenesis. CEP290 is also important for the ciliary targeting of Rab8, a small GTPase that 
is regulated by Bardet-Biedel Syndrome (BBS) protein complex (the BBSome) in 
ciliogenesis (Kim et al., 2008).  
To assess the effect of the transient knockdown of CEP290 on prostate cancer cell 
proliferation 
3
H thymidine incorporation proliferation assays was perforemed. The 
3
H 
Thymidine incorporation was assessed following CEP290 siRNA silencing. Briefly, 5x10
4
 
cells/well were cultured in 24-well plates and transfected with the designed CEP290 siRNAs 
and at 24, 48 and 72 hours. 
3
H thymidine (
3
H-Thy) uptake was assessed 18 hours after adding 
thymidine, the media was removed and the cells were washed and  transferred into 96-well 
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round bottom plates. Plates were then harvested using a cell harvester onto 96 Uni/Filter 
scintillation plates and were counted using a Top-Count scintillation counter.  
The 
3
H Thymidine incorporation (proliferation) assay showed significant reductions in 
cellular proliferation at 24, 48 and 72 hours post CEP290 siRNA transfection, particularly for 
PC3 cell proliferation. In contrast, DU145 showed no significant reductions in cellular 
proliferation at 24, 48 and 72 hours following CEP290 siRNA treatment. The three CEP290 
siRNAs were assessed in comparison to cells growing normally (without transfection) in 
order to ensure that these findings were due to a reduction in CEP290 and not a consequence 
of the transfection procedure used. All of the above experiments were performed on cells that 
had undergone transient transfection to confirm that the time coarse transfection had the same 
effect on cell proliferation. However, these results are inconclusive since for PC3 cells 
addition of control siRNA reduced cell proliferation to same extent as CEP290 siRNA and 
DU145 proliferation was unaffected by siRNAs’ treatment.  
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(A) Effect of CEP290 knockdown on PC3 cell proliferation 
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Figure 3.2.3. 1 
3
H Thymidine incorporation (proliferation) assay to assess the effect of 
CEP290 siRNA treatment on PC3 cells.  
Measurements were taken over time (24, 48 and 72 hours). Statistical significance (*p<0.05) 
(**p<0.01) (***p<0.001) (****p<0.0001) as determined by student’s t test. 
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(B) Effect of CEP290 knockdown on DU145 cell proliferation 
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Figure 3.2.3. 2  
3
H Thymidine incorporation (proliferation assay) to assess the effect of 
CEP290 siRNA treatment on DU145 cells.  
Measurements were taken over time (24, 48 and 72 hours). Statistical significance (*p<0.05) 
(**p<0.01) (***p<0.001) (****p<0.0001) as determined by student’s t test. 
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3.3 Discussion: 
 
T21 is a novel prostate Tumour-Associated Antigen (TAA) and has been shown to elicit a 
humoral immune response in prostate cancer patients (Mile et al. 2007; Mile et al. 2012). T21 
has also been shown to be over-expressed in malignant glands of prostate cancer compared to 
benign glands and stroma at both the mRNA level and protein expression. T21 shares 
significant similarity with a Centrosomal Protein called CEP290. This large protein has been 
implicated in several cilia related syndromic disorders such as Joubert syndrome (Sayer et al, 
2006; Valente et al, 2006). Consequently, it was necessary to determine the differences 
between these two molecules to facilitate further studies on the role of T21 in prostate cancer 
tumourigenesis. Quantitative RT-PCR using specific primers to CEP290 and T21, showed 
that T21 is a separate product, different from CEP290, however the levels of expressions of 
these two molecules in tissues and cell lines did not always correlate, which made the 
analysis difficult. Many researchers have reported on the fact that the levels of expression of 
RNA products do not necessarily reflect the level of expression of the corresponding protein 
products. CEP290 itself may indeed be a cancer associated protein leading to anti-CEP290 
antibody production, which has been identified in gastric (Chen & Shou, 2001), CTCL 
tumours and also leukaemia and melanoma cell lines (Eichmuller et al., 2001). 
To investigate CEP290 and T21 expression further, a custom made polyclonal antibody was 
used to study T21 protein expression. For CEP290 protein expression, a commercial antibody 
was purchased and used. Unfortunately, immunofluorescence studies using the polyclonal 
antibody, failed to show specificity for T21 protein as this antibody appears to also recognise 
CEP290. Therefore a new antibody directed against the unique region of T21 was produced. 
Remarkably, this antibody recognised specifically T21 both by immunofluorescence and 
immunoblotting.  The fluorescent immunostaining with the unique T21 antibody confirmed 
that T21 did not localise to the centrosomes (Figure 3.2.1.3). Following immunofluorescent 
staining of the prostate cancer cell lines with the new (specific) T21 antibody there was a 
clear demonstration of cytoplasmic staining in all three cell lines which is consistent with the 
predicted cellular localisation of this protein. From these results it can be inferred that T21 is 
unlikely to share a functional role similar to that of CEP290 at the centrosomal sites during 
cell proliferation. 
An important question that until now has remained unanswered was the nature and 
relationship between T21 and CEP290. To date mRNA levels failed to distinguish any 
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associations in expression of the two protein and so far western blot analysis concluded a 
seemingly lower expression of T21 compared to CEP290 in prostate cancer cell lines.  
Therefore, CEP290 knockdown was performed using siRNAs in order to assess its effect on 
mRNA T21 expression. CEP290 was efficiently silenced in PC3 and DU145 using siRNA 
and the transfected cells were observed by microscopy for changes in cell behaviour and 
morphology during in vitro culture. In summary, cells treated with CEP290 siRNAs did not 
exhibit any noticeable changes when compared with control siRNA or interferon treatment 
other than a seemingly reduced capability to proliferate. Following this observation, 
experiments assessing cell proliferation were performed using 
3
H thyimidine incorporation 
parallel to assesse mRNA T21 knockdown following CEP290 siRNAs transfection. mRNA 
T21 reduction was observed only with CEP290 siRNA 3, in contrast to CEP290 siRNA 1 and 
2 that silenced CEP290 within 24 hours but showed no effect on T21 mRNA levels, 
suggesting independent expression of these two genes.   
As CEP290 has been found to be involved in centrosomal function, it could naturally be 
concluded that its presence would be in some way be linked to proliferating cells. This was 
evident in earlier studies using T21/CEP290 siRNA in prostate cancer cells; following 
reanalysis of affymetrix data for CEP290 pathway markers, genes known to be implicated in 
CEP290 pathways were significantly modified following T21/CEP290 siRNA transfection. 
As a consequence of the previous investigation into T21 and its more recently confirmed 
association with CEP290, it was critical to establish the link between CEP290 and T21 with 
regard to cellular proliferation post CEP290 knockdown to determine further the potential 
role (if any) of T21 in cancer progression. The results were inconclusive since the control 
siRNA reduced PC3 proliferation similarly to CEP290 siRNA and expression with DU145 
did not show loss of proliferation. This aspect of the study requires further investigation and 
optimisation (Figure 3.2.3.1 and 3.2.3.1.2).  
The emerging evidence for T21’s role in prostate cancer and also the fact that T21 is a novel 
transcript as demonstrated in this part of study infers that T21 has the potential to be a target 
for cancer therapy. Since the molecular function of this novel transcript (T21) remains 
undetermined, subsequent chapters will focus on elucidating some of the key pathways that 
T21 is implicated in. 
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CHAPTER IV 
THE EFFECT OF T21 KNOCKDOWN ON KEY 
CELLULAR PATHWAYS THROUGH THE 
ANALYSIS OF GENE EXPRESSION PROFILES 
OBTAINED BY NEXT GENERATION 
SEQUENCING (NGS) 
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4 CHAPTER FOUR: The effect of T21 knockdown on key cellular 
pathways through the analysis of gene expression profiles obtained by 
Next Generation Sequencing (NGS) 
4.1 Introduction 
As discussed in the previous chapter, T21 and CEP290 were shown to be different protein 
products as demonstrated through the study of their mRNAs and proteins using molecular 
and cellular approaches. Further confirmation was achieved by silencing CEP290 using 
specific siRNA that showed no significant impact on the unique sequence of T21.  Therefore, 
despite the shared sequence similarity between T21 and CEP290, the function and 
interactions of T21 are likely to be distinct. The expression of T21 has been reported to be 
highly associated with the pathological stage of tumour progression and this aspect of the 
present study was designed to investigate the potential role of T21 in prostate cancer.  
In 2001 the first sequencing of the human genome was reported by an international 
consortium, which provided extensive resources and a basis for further research into the 
regulatory pathways of cell behaviour (Lander et al, 2001; Venter et al, 2001). Since then, 
genomic research has expanded dramatically, leading to a revolution in the development of 
new technologies with high-throughput capability. For instance, during the past decade, 
microarray-array based experiments have been extensively applied for research into the 
cancer genome and transcriptomes, which has provided further insight into the molecular 
genetics associated with breast cancer (Sotiriou and Pusztai, 2009). Nonetheless, microarray-
based expression profiling alongside genomic hybridisation data analysis has encountered 
crucial limitations. The profiling of microarray data provides a semi-quantitative analysis that 
is restricted due to the nature of the probes, which can affect both sensitivity and specificity. 
On the other hand, comparative genomic hybridisation and Single Nucleotide Polymorphism 
(SNP) provides abundant information on abnormal gene copy number(s), but without 
knowledge of structural genomic abnormalities and nucleotide base-pair mutations (Tan et al, 
2007). Consequently, automated sequencing tools were developed to further characterize 
genomic structure and function, providing an extensive amount of information in a relatively 
short time frame with qualitative and quantitative data on any single gene expression, down 
to the single nucleotide level. Among, these tools, Next Generation Sequencing (NGS) is 
certainly a revolutionary and effective technology that has been developed, providing 
unprecedented parallel sequencing power, which encompasses several different 
methodologies for characterization of complex genetic disorders (including cancer) at their 
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genomic, transcriptomic and epigenomic levels (Venter et al, 2003; Margulies et al, 2005; 
Shendure and Hanlee, 2008; and Reis-Filho, 2009).  
The recent development of NGS technologies has provided a platform for performing low 
cost high-throughput sequencing. Two of the common NGS platforms currently used in 
research and clinical labs are the Life Technologies Ion Torrent Personal Genome Machine 
(PGM) and the Illumina MiSeq which have been extensively used to investigate the 
molecular characteristics of disease. These platforms have similar basic methodology in 
terms of template preparation, sequencing, imaging, and data analysis. However, each 
platform has unique aspects in how sequencing is accomplished (Figure 4.1.1) (Metzker, 
2010; Grada and Weinbrecht, 2013). NGS, nonetheless, poses a considerable challenge 
related to data storage, analysis and solutions management. Therefore, this powerful 
technology requires further advanced bioinformatics tools that are essential for successful 
NGS applications (Zhang et al, 2011). 
This part of the study has focused on analysing the effect of T21 knockdown on whole 
genome expression in PC3 prostate cancer cells using Next Generation Sequencing (NGS). 
The data obtained were analysed using bioinformatics tools to identify the genes 
differentially expressed in T21 knockdown and its corresponding control.  Moreover, 
potential important pathways were identified from NGS data analysis. Further investigations 
of these pathways using stable knockdown of T21 (shRNA) was subsequently performed to 
analyse changes in protein expression using proteome profiler arrays (performed and 
discussed in Chapter 5). 
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Figure 4.1. 1 Next-generation sequencing (NGS) methodology for the most two common 
platforms (Ion Torrent Personal PGM and the Illumina MiSeq). 
 (Adapted from Grada A and Weinbrecht K, 2013). 
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4.2 Results: 
4.2.1 T21 silencing using small interfering RNA (siRNA): 
 
T21 silencing is an experimental technique that was performed in order to understand the role 
of T21 in prostate cancer. First of all, three small interfering RNAs (siRNAs) were designed 
within the unique region of T21 and used to silence gene expression in PC3 prostate cancer 
cell line. Then, total RNA was extracted from cells using RNA spin columns after 24, 48 and 
72 hours post T21 silencing and assessed at the mRNA level by qRT-PCR using T21 specific 
primers. The data showed that T21-siRNA 3 had a significant effect in silencing T21 after 48 
hours (Figure 4.2.1.1). siRNA 1 and 2 knockdown did not have significant effects at 24, 48 
and 72 hours post-transfection. 
In parallel, of assessing the efficiency of T21 mRNA knockdown, investigation of the effect 
of T21 knockdown on cellular proliferation was assayed using 
3
H thymidine incorporation 
assay over period of time (24, 48 and 72 hours). Interestingly, the data demonstrated a 
significant reduction of the proliferation observed in PC3 cells transfected with T21 siRNA 3 
and when compared to control siRNA after 48 and 72 hours (Figure 4.2.1.2). No significant 
effect on PC3 cell proliferation was observed after 24 hours post-transfection. 
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       (A)                                                                 (B) 
                                          
                                           
 (C) 
 
Figure 4.2.1. 1 T21 knockdown of a T21 expression using a prostate cancer cell line 
(PC3). 
 Time course was performed using quantitative real time PCR showing T21 siRNA silencing 
over time (A) 24 hours, (B) 48 hours and (C) 72hours. Experiments were carried out three 
times in duplicate (n=3). Results are given as the standard error of the mean, normalised for 
relative expression of T21-siRNA and negative control siRNA. Statistical significance is 
indicated (****p<0.0001 for 48 hours) as determined by Student’s t test. 
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Figure 4.2.1. 2 Cellular proliferation assay following T21 specific siRNA 3 transfection 
in PC3 cells. 
 Time course performed using a 
3
H thymidine incorporation assay to demonstrate reduced 
PC3 cell proliferation following T21- siRNA silencing over time (A) 48 and (B) 72 hours. 
Experiments were carried out in triplicate wells (n=3) on three separate occasions 
represented with standard error of the mean. Statistical significance indicated (***p<0.0004 
for 48 hours and ***p<0.0003 for 72 hours) as determined by Student’s t test. 
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4.2.2 Investigating the effect of T21 knockdown on key cellular pathways through the 
analysis of gene expression profiles obtained by Next Generation Sequencing 
(NGS) 
 
This study has focused on elucidating the role of T21 in the regulation of key cellular 
pathways in prostate cancer. Following successful T21 silencing in the PC3 prostate cancer 
cells (was previously performed by Drs. Amanda Miles and Morgan Mathieu), Next 
Generation Sequencing (NGS) was used to determine the effect of T21 silencing on gene 
expression.  The cells treated with either control siRNA or T21 siRNA were lysed using RNA 
STAT-60 and the total RNA was extracted using isopropanol precipitation. The RNA quality 
was assessed using a RNA 6000 pico chip kit (Agilent) and an Agilent 2100 Bioanalyzer 
(Agilent). RNA samples with RNA integrity number (RIN) values between 8 and 10 were 
stored at -80°C until analysis by next generation sequencing (NGS). RNA samples with RIN 
values below 8 were discarded. 
Next generation sequencing of total RNA samples were outsourced and carried out by the 
Gene Service from Source Bioscience. Libraries were created by producing a series of 
randomly fragmented RNA to which two adapters were linked. These libraries were then 
denatured to single molecules and randomly hybridised to the surface of a flow cell to form 
clusters. Once the latter were formed, the flow cell was sequenced on the Illumina Genome 
Analyser IIx platform using 38bp single end reads. Alignment of the reads against the human 
genome was performed by the Bioinformatics Service from Source Bioscience. Technical 
repeats were merged and logarithmic (fold-change) values and p values were calculated to 
determine significant differences (Table 4.2.2.1 A and B). 
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Figure 4.2.2. 1 Workflow illustrating the steps performed for Next Generation 
Sequencing (NGS) sample preparation. 
In brief, hundreds of millions of DNA fragments were sequenced simultaneously. Sequencing 
was performed by extending one base at a time in the chemistry process, based on reversible 
single base extensions. Four fluorescently reversible dideoxynucleotides (ddA, ddC, ddG and 
ddT) are introduced in the flow cell simultaneously. These bases compete with each other to 
bind to the template. Natural competition ensures the highest accuracy. Following the 
chemistry, the instrument takes a picture for each added base and saves the image in a tiff 
format. The fluorophore is then cleaved and the 3’ hydroxyl end is de-protected for the next 
reversible single base extension.  This process is done in many cycles and each cycle includes 
the chemistry step as well as the imaging step.  For each cycle, hundreds of tiff images are 
generated. Specialised RTA (Real-Time Analysis) software loaded onto the platform 
automatically converts scanned images into digital intensity signals, and interprets these 
signals as nucleotide bases. Over a specified number of cycles, these bases are combined to 
generate millions of lines of raw sequence data, or “reads” as shown in tables (Table 4.2.2.1 
A and B). These data were used and categorised according to the potential pathways of each 
genes and its involvement in tumourigensis.   
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(A) 
test_ID Gene Locus Sample_1 Sample_2 Status Value_1 Value_2 
ln(fold_ 
change) test_stat p_value Significant 
XLOC_0
38816 MAPK6 
chr15:52311
416-
52358462 
PC3_ 
control 
PC3_ 
siRNA OK 219.79 103.84 -0.749777 6.29648 3.04E-10 Yes 
XLOC_0
34098 CALM3 
chr19:47104
565-
47114039 
PC3_ 
control 
PC3_ 
siRNA OK 776.38 372.08 -0.73554 10.8804 0 Yes 
XLOC_0
26153 HIPK2 
chr7:139246
315-
139720123 
PC3_ 
control 
PC3_ 
siRNA OK 636.09 325.71 -0.669348 10.1078 0 Yes 
XLOC_0
29074 RAP2A 
chr13:98086
475-
98120244 
PC3_ 
control 
PC3_ 
siRNA OK 376.56 199.03 -0.637602 6.8739 6.25E-12 Yes 
XLOC_0
22135 BCL10 
chr1:857314
63-86043933 
PC3_ 
control 
PC3_ 
siRNA OK 165.7 99.402 -0.511033 6.72187 1.79E-11 Yes 
XLOC_0
38894 MAP2K1 
chr15:66679
154-
66790146 
PC3_ 
control 
PC3_ 
siRNA OK 441.56 270.41 -0.490364 7.53079 5.05E-14 Yes 
XLOC_0
23352 TP53BP2 
chr1:223967
595-
224033674 
PC3_ 
control 
PC3_ 
siRNA OK 170.58 104.93 -0.485883 3.04592 0.00232 Yes 
XLOC_0
25750 CDK6 
chr7:922342
34-92546501 
PC3_ 
control 
PC3_ 
siRNA OK 140.67 90.605 -0.439898 3.0797 0.002072 Yes 
XLOC_0
29013 NDFIP2 
chr13:80051
498-
80130210 
PC3_ 
control 
PC3_ 
siRNA OK 203.44 132.6 -0.428058 3.29346 0.00099 Yes 
XLOC_0
17277 CEP290 
chr12:88429
267-
88535084 
PC3_ 
control 
PC3_ 
siRNA OK 31.688 17.128 -0.615205 2.95058 0.003172 Yes 
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(B) 
           
test_ID Gene Locus Sample_1 Sample_2 Status Value_1 Value_2 
ln(fold_ 
change) test_stat p_value Significant 
XLOC_0
05051 CHD8 
chr14:21853
357-
21905404 
PC3_ 
control 
PC3_ 
siRNA OK 100.554 186.034 0.615233 -4.96775 6.77E-07 Yes 
XLOC_0
43823 TP53INP2 
chr20:33284
721-
33302432 
PC3_ 
control 
PC3_ 
siRNA OK 89.767 145.21 0.480951 -3.43546 0.000592 Yes 
XLOC_0
14239 DUSP14 
chr17:35441
922-
36244363 
PC3_ 
control 
PC3_ 
siRNA OK 94.724 161.27 0.532127 -12.8714 0 Yes 
XLOC_0
43316 IGFBP5 
chr2:217536
827-
217858722 
PC3_ 
control 
PC3_ 
siRNA OK 66.188 113.43 0.538673 -3.25888 0.001119 Yes 
XLOC_0
34522 ZBTB7A 
chr19:40452
16-4066816 
PC3_ 
control 
PC3_ 
siRNA OK 43.151 77.388 0.584114 -3.07444 0.002109 Yes 
XLOC_0
12925 FRS3 
chr6:417379
13-41757879 
PC3_ 
control 
PC3_ 
siRNA OK 12.646 24.5 0.661342 -10.5106 0 Yes 
XLOC_0
10527 RAB6B 
chr3:133502
876-
133614680 
PC3_ 
control 
PC3_ 
siRNA OK 1.1811 2.4189 0.716824 -4.52293 6.10E-06 Yes 
XLOC_0
37757 FGF1 
chr5:141689
991-
142077635 
PC3_ 
control 
PC3_ 
siRNA OK 156.83 329.66 0.742906 -28.8754 0 Yes 
XLOC_0
35591 PDZD2 
chr5:316395
16-32122047 
PC3_ 
control 
PC3_ 
siRNA OK 14.21 33.148 0.847034 -5.91178 3.38E-09 Yes 
XLOC_0
34165 BCL2L12 
chr19:50162
828-
50177172 
PC3_ 
control 
PC3_ 
siRNA OK 141.25 376.91 0.981467 -15.9198 0 Yes 
 
Table 4.2.2. 1 Examples of genes down regulated and up regulated genes obtained by NGS following T21 knockdown in PC3 cell line. 
 (A) Down Regulated and (B) Up Regulated Genes. Selection was based on a minimal 2 fold-change of relative expression to the control and the 
published literature indicating the role of the gene specific in cancer or its involvement in processes known to be altered in cancer cells. 
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Threshold cut off of values above (up-regulated expression) and below (down-regulated 
expression) 2 fold-changes were applied to determine significant gene regulation changes. 
Although a complete bioinformatics analysis and experimental validation of gene expression 
was performed, genes that were either significantly down regulated (26 genes) or up 
regulated (197 genes) following T21 siRNA knockdown were used for further analysis 
(Figure 4.2.2.2).  Following a more focused examination of gene functions and literature 
searches, a more refined shortlist of 20 genes in total (10 up regulated and 10 down regulated 
genes) that were cancer-associated were selected for more detailed examination. 
The functions of genes undergoing significant changes of expression were then obtained 
online using a variety of web tools such as OMIM (http://www.ncbi.nlm.nih.gov/omim/), 
Uniprot (http://www.uniprot.org/ ), and GeneCards (http://www.genecards.org/). 
In summary, the down and up regulated genes were chosen based on their potential pathways 
and their features involved in each pathways in order to understand their role in T21-
mediated tumour progression. For instance, cell cycle pathways include several genes such as 
MAPK6, CALM3 and CDK6 which were shown from NGS data as down regulated genes as 
a result of T21 knock down. ZBTB7A, in contrast, has a role in cell cycle pathways as a 
repressor of the CDKN2A gene transcription and represented by NGS data as an up regulated 
gene following T12 silencing. Other genes known to be involved in apoptosis were also 
significantly down-regulated or up-regulated such as HIPK2, BCL10 and BCL2L12, a 
member of BCL family, which play a role in regulating apoptosis. RAS oncogene family and 
MAP kinase pathways were also found present in the NGS data as either down-regulated or 
up regulated upon T21 knockdown. The list of selected genes based on their potential 
pathways are summarised in Table 4.2.2.2 (A) and (B) for the down and up regulated genes 
respectively.        
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(A) 
 
(B) 
 
Figure 4.2.2. 2 Bioinformatics analysis of cellular pathway(s) that are altered following 
knockdown of T21 using bioinformatics tools.  
The data obtained from NGS following T21 knockdown experiment in PC3 prostate cancer 
cell line were used for the Several genes which were categorised (A) Down-regulated and (B) 
Up-regulated; and only those with a significant fold change were selected. 
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(A) 
Gene Pathway? Down regulated when T21 knockdown  
MAPK6 cell cycle Ser/Thr protein kinase may promote entry in the cell cycle  
CALM3 cell cycle regulates the centrosome cycle and progression through 
cytokinesis 
HIPK2 apoptosis Inhibits cell growth and promotes apoptosis 
RAP2A   RAP2, member of RAS oncogene family 
BCL10 apoptosis Promotes apoptosis 
MAP2K1   Activates ERK1 and ERK2 MAP kinases 
TP53BP2 apoptosis apoptosis-stimulating protein of p53 
CDK6 cell cycle involved in the control of the cell cycle 
NDFIP2   May modulate EGFR signaling 
CEP290 cell cycle Activates ATF4-mediated transcription 
 
(B) 
Gene Pathway? Up regulation when T21 knockdown 
CHD8 proliferation 
 
Suppresses p53/TP53-mediated apoptosis, negative regulator of 
Wnt signaling pathway 
TP53INP2 p53 pathway tumor protein p53 inducible nuclear protein 2 
DUSP14  Cell growth 
regulation 
Involved in the inactivation of MAP kinases. Dephosphorylates 
ERK, JNK and p38 MAP-kinases 
IGFBP5 cell 
growth/survival 
IGF-binding proteins prolong the half-life of the IGFs 
ZBTB7A cell cycle Specifically represses the transcription of the CDKN2A gene. 
FRS3 ras pathway function in linking FGF receptor stimulation to activators of Ras 
RAB6B ras pathway RAB6B, member RAS oncogene family 
FGF1 cell cycle/mets The heparin-binding fibroblast growth factors play important 
roles in the regulation of cell survival, cell division, angiogenesis, 
cell differentiation and cell migration. 
PDZD2 cell cycle and 
immune 
activation 
Up-regulated in primary prostate tumors and may be involved in 
the early stages of prostate tumourigenesis. 
BCL2L12 anti/pro 
apoptosis 
BCL2 family members form hetero- or homodimers 
BCL family act as anti or pro-apoptotic regulators 
 
Table 4.2.2. 2 List of selected genes classified into different groups corresponding to 
their function within the cell. 
 Gene selection was based on a minimal 2 fold-change (FC) of expression to control and 
published literature indicating the role of the gene specific to cancer or its involvement in 
processes known to be altered in cancerous cells. 
 
To confirm the results obtained by NGS, specific primers for the selected genes which were 
found down-regulated and up regulated genes were designed and optimised (list of primers - 
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Chapter 2) for qRT-PCR and using the PC3 prostate cancer cell line mRNA treated with 
siRNA (T21 vs control). The mRNAs were obtained from the treated cells after knockdown 
24 to 48 hours post-transfection of siRNAs. As a control, relative expressions of these genes 
were normalised to the House Keeping Genes HKGs (TBP-1 and HPRT-1).  The results 
obtained by qRT-PCR confirmed and validated the results obtained by NGS for the selected 
down-regulated and up-regulated genes (Figure 4.2.2.3 and Figure 4.2.2.4).  
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Figure 4.2.2. 3  qRT-PCR analysis of the down regulated genes, selected from NGS data.  
These genes were down regulated as a result of T21 knockdown using siRNA in PC3 cell line. 
The relative expression (ΔCt) of each gene was normalised to House Keeping Genes (HKGs) 
TBP-1 and HPRT-1 primers. Statistical significance indicated (****p<0.0001, ***p<0.001, 
**p<0.01) was determined by Student’s t test. 
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Figure 4.2.2. 4 qRT-PCR validations of the selected up-regulated genes, selected from 
NGS data. 
 These genes were up-regulated following T21 siRNA transfection of PC3 cells. The relative 
expression (ΔCt) of each gene was performed by using qRT-PCR and normalised to House 
Keeping Genes (HKGs) TBP-1 and HPRT-1 primers. Statistical significance (****p<0.0001, 
***p<0.001, **p<0.01) was determined by Student’s t test. 
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4.3 Discussion: 
 
In this chapter experiments were performed using gene silencing techniques to determine the 
potential role of T21 in cancer progression. Firstly, three siRNA oligonucleotides designed 
within the unique region of T21 were synthesised and transfected into PC3 cells. Only one 
siRNA led to the knockdown of T21 (T21-siRNA3) achieving the most significant 
knockdown in expression of both mRNA and protein between 24 hour and 48 hours post-
transfection. No noticeable changes occurred in cell morphology; however cells treated with 
T21 siRNA were seemingly hindered in their capacity to proliferate.  Cellular proliferation 
assays using 
3
H Thymidine incorporation confirmed this observation after 48 and 72 hours 
following T21-siRNA transfection. Furthermore, other knockdown experiments were 
performed using T21 specific shRNA transfection, which was employed to study the long 
term effects of T21 silencing on transfected cells and used for proteome profiler arrays in 
chapter 5. As the transient knockdown of T21 in PC3 cells using T21-siRNA was more 
reliable at this stage, it has been used to confirm the NGS data. The results indicated that 
several pathways important for cell proliferation and survival, centrosome and structural 
rearrangement and cell cycle control were affected. As an example, some MAPK pathways 
were clearly down-regulated upon T21mRNA knockdown such as MAPK6 (Mitogen 
Activated Protein Kinase 6) and MAP2K1 (Mitogen-Activated Protein Kinase Kinase 1). 
MAPK6 and MAP2K1 are members of the mitogen activated protein kinase (MAPK) 
signalling network which represents another molecular cascade that has been shown to be 
vastly modified in tumour cells. Much like the PI3K pathway, MAPK is involved in a series 
of events governing cell behaviour, ranging from proliferation through to differentiation, 
apoptosis, migration and cell transformation (Huang et al, 2004; Kim and Choi, 2010). 
Whereas PI3K is a single line of communication, MAPK consists of a series of different 
pathways that interact with one another to bring about their action (Qi et al., 2005). 
The MAPK pathways essentially are used to link the extracellular signals to the machinery 
that control cellular processes such as growth, proliferation, differentiation, migration and 
apoptosis (Dhillon et al., 2007). The MAPK signalling abnormalities may affect most, if not 
all, of these processes and play a critical role in the development and progression of cancer. 
Selected down regulated genes were chosen from NGS data that showed significant fold-
changes by using bioinformatics tools for modeling the MAPK pathways. MAPK6, mitogen-
activated protein kinase 6, for instance, represented as Ser/Thr protein kinase which appears 
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to have a role in promoting the cell cycle. MAP2K1, in addition, as a member of MAPK 
family has a role in activation of the ERK pathway through ERK1 and ERK2 MAP kinases. 
The ERK pathway is deregulated in approximatly one third of all human cancers (Dhillon et 
al., 2007). Briefly, ERK1 and ERK2 are activated due to phosphorylation by MEK1 and 
MEK2 which are themselves activated when phosphorylated by Raf-1, B-Raf and A-Raf . 
Numerous extracellular signals can activate ERK signalling and the corresponding pathways 
whereby growth factors and mitogens activate ERK signalling in particular are correlated to 
cancer (Downward, 2003). MAPK pathway modulation has also been reported to influence 
chemotherapeutic drugs and may enhance or decrease drug efficacies (Boldt et al., 2002). 
RAS proteins, on the other hand, have a role in controlling signalling pathways as key 
regulators of several aspects of normal cell growth and malignant transformation. RAS can 
gain abnormalities due to activating mutations in the RAS genes in most human tumours as 
well as alterations within upstream or downstream signalling components. Thus, the RAS 
pathway can be targeted in order to inhibit tumour growth, survival and metastasis and has 
been considered for immunotherapeutic intervention (Downward, 2003). The RAP2A gene is 
down regulated, as shown by NGS as a consequence of T21 knockdown in PC3 cells and is a 
member of RAS oncogene family.  It can be inferred therefore that T21 is involved in 
maintaining and/or enhancing the expression of genes important in cancer.  Interestingly, 
other pathways involved in signalling transduction events were up-regulated following T21 
downregulated. As an example, DUSP14 is a dual-specificity cysteine-based protein-tyrosine 
phosphatase that belongs to the DUSPs family of molecules involved in the de-
phosphorylation of cellular kinases implicated in proliferative and survival transduction 
signalling such as ERK, JNK and p38 MAP kinases pathways (Patterson et al., 2009). 
IGFBP5 (insulin-like growth factor binding protein 5), is another pro-proliferation and pro-
survival molecule involved in promoting the function of the Insulin Growth Factor IGF-1. 
IGFBP serves as a carrier for IGF-1 which prolongs its half-life in a cell and tissue specific 
manner and therefore enhances its pro-proliferation and pro-survival functions (Beattie et al., 
2006). FRS3 (Fibroblast Growth Factor Receptor Substrate 3) acts as an adapter that links 
FGF and NGF receptors to downstream signalling pathways and may be responsible through 
this mechanism of the activation of the MAP kinase signalling pathways (Dixon et al., 2006).  
In addition, it also observed an up-regulation of those genes that would inhibit the response to 
DNA damage and those that modulate immune responses. Conversely, genes involved in 
regulatory pathways were suppressed in the presence of T21 and included RAS family 
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members, cell stress/DNA repair pathways and the PI3K-Akt pathway. Although a full and 
through analysis is essential to elucidate pathways that may involve T21 activity, the data 
presented here indicate that T21 appears to be involved in promoting tumourogenesis and 
therefore could represent an attractive target for therapy. 
It was observed that cyclin-dependent kinase 6 (CDK6) was down regulated following T21 
knockdown; CDK6 is involved in cell cycle progression and differentiation (Grossel et al., 
2006).  Moreover, TP53BP2 which is an apoptosis- stimulating protein of tumour suppressor 
protein 53 (p53), was down regulated upon T21 silencing. The data presented here also 
indicates the up regulation of genes that are involved, for instance, in the promotion of 
tumourogenesis through cell proliferation and cell cycle control such as MAPK6, or 
overriding DNA damage pathways and promoting cell survival like HIPK2 occurs as a result 
of T21 silencing. The up regulation of genes such as CALM3 and RAB3IP may be indicative 
of a more specific role T21 plays in centrosomal and structural rearrangement during mitosis. 
Moreover, genes that were suppressed following T21 silencing play regulatory roles in 
tumour progression through regulation of RAS family (RAB6B, FRS3), cell stress/DNA 
repair pathways (CHD8) (Nishiyama et al., 2009) or genes that are involved in the Akt 
pathway. Although the molecular characterisations of NGS data were selected and 
successfully validated using qRT-PCR outcomes, further investigations at the protein level 
are required in order to confirm a functional role. Therefore, proteome profiler arrays were 
used to further address this issue (chapter 5). 
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CHAPTER V 
EXPRESSION OF T21 AND ITS IMPACT ON 
CELL SIGNALLING PATHWAYS IN CANCER 
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5 CHAPTER FIVE: Expression of T21 and its Impact of Cell Signalling 
Pathways in Cancer 
5.1 Introduction: 
 
Cancer is a complex cellular disorder characterised by disruptions in signaling pathways that 
control cell homeostasis and functions. Cell behaviour is governed by complex cascades of 
molecular events that instruct the cell to react to external signals within the environment and 
according to their lineage and differentiation status. Therefore, alterations in normal cell 
signaling pathways will affect the function of other proteins, including transcription factors, 
which may alter the expression of targeted genes. An array of signaling networks include 
interactions by a diverse and extensive numbers of molecules and these networks might 
operate as a single cascade or multiple pathways to determine specific cellular activities. 
Tumorigenesis requires deregulation of at least at least six cellular processes (Johnson et al., 
1996) in order to acquire the capabilities of cell proliferation signal independency, apoptosis 
evasion, anti-growth signal insensitivity, unlimited replicative potential, the ability to invade 
and metastasis and to promote and maintain angiogenesis for nutrient supply (Hanahan and 
Weinberg, 2000). Moreover, it has been conclusively demonstrated that MAPK signaling 
abnormalities are involved in most if not all these processes, and play important roles in 
cancer development and progression (Downward, 2003; Wellbrock et al., 2004; Kolch, 2005; 
Bradham and McClay, 2006; Galabova-Kovacs et al., 2006; Kohno and Pouyssegur, 2006; 
Torii et al., 2006).  
  
Mitogen-activated protein kinase (MAPK) pathways are activated by extracellular signals 
mediated by growth factors, cytokines, stress proteins or mitogens which subsequently 
modulate and control crucial cellular processes such as growth, proliferation, differentiation, 
migration and apoptosis (Dhillon et al, 2007). Signaling via the MAPK pathways involving 
multiple kinase phosphorylation events, as shown in Figure 5.1.1. Six fundamental groups of 
MAPKs have been identified  to date in mammals; extracellular signal-regulated kinase 
(ERK)1/2, ERK3/ 4, ERK5, ERK7/8, Jun N-terminal kinase (JNK)1/2/3 and the p38 isoforms 
α/β/ϒ (ERK6)/δ (Schaeffer and Weber, 1999; Chen et al., 2001; Kyriakis and Avruch, 2001; 
Krens et al., 2006). 
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Figure 5.1. 1 Schematic diagram of a MAPK cascade. 
 It represents phosphorylation of MAP kinase kinase kinase (MAPKKK) which in turn 
phosphorylates MAP kinase kinase (MAPKK), which then phosphorylated MAP kinase 
(MAPK) (Adapted from Neill et al. 2001). 
 
The PI3k (Phosphoinositide 3-kinase) signaling pathway is dominant major signaling cascade 
that acts downstream of growth factor receptor tyrosine kinases (RTKs) (Cantley, 2002). 
PI3K plays a role in regulating the lipid second messenger phosphatidylinositol-3, 4, 5-
triphosphate (PIP3) production at the cell membrane. Consequently, PIP3 leads to the 
activation of a broad range of downstream targets such as the activation of the serine-
threonine protein kinase Akt.  The PI3K-Akt signaling pathway of PI3K-Akt has a role in 
conducting and regulating various cellular processes including, survival, cell growth and 
apoptosis that are altered during tumourigenesis. The involvement of PI3K/Akt pathway in 
oncogenesis has been extensively investigated and has become a prime target for cancer 
therapies (Vivanco and Sawyers, 2002; Chang et al, 2005). Moreover, Akt is a primary 
mediator of PI3K-initiated signaling and has a number of critical downstream substrates such 
as the cAMP-response-element-binding protein (CREB) signaling which has been reported to 
be associated with malignant transformation (Son J et al, 2010). CREB is activated as a result 
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of Akt phosphorylation and leads to glycogen synthase kinase-3 (GSK-3) inactivation which 
promotes cell survival and cell cycle progression (Figure 5.1.2) (Nicholson and Anderson, 
2001 ). GSK-3 phosphorylates several transcription factors such as c-Myc, c-Jun, and c-Myb 
and the translation factor eIF2B (Plyte et al., 1992; Welsh et al., 1996). The uncontrolled 
frequent signaling through the PI3K pathway can be due to PTEN loss as a result of 
chromosomal deletion (Blanco-Aparicio et al., 2007), which in turn affects phosphorylation 
leading to post-translational modifications that affect protein activity.   Furthermore, PTEN 
loss also increases PIP3 production and modifies Akt activity (Maehama and Dixon, 1998; 
Chow and Baker, 2006) leading to an increase in cellular proliferation and gene transcription 
and inhibition of apoptosis by inhibiting the activity of other proteins, for example BAD 
(Datta et al, 1997). 
The changes in cell signaling that occur in cancer is significantly influenced and determined 
by dominant and recessive genetic events, mediated by oncogenes and tumour suppressor 
genes respectively. Subsequently, proto-oncogenes and tumour suppressor gene are 
significantly modified in cancer, leading to the production of proteins with post-translational 
modifications. For example, RAS and B-RAF point mutations will lead to a significant 
increase in cellular proliferation via either the PI3K or MAPK pathways (Bos, 1989; Davies 
et al., 2002).  In addition altered p53 activity/function, which occurs as a result of point 
mutation, will reduce its capability of mediating cell cycle arrest and apoptosis, thus further 
contributing to increase cell proliferation (Levine and Oren, 2009). 
The data reported in the previous chapter highlighted the involvement of T21 in tumour cell 
proliferation. These studies also indicated that various genes involved in the regulation of 
various cellular processes are affected by T21 down regulation. To investigate further the 
effect of T21 on cell proliferation, this aspect of the research focused on the analysis of 
kinase pathways in a setting where T21 expression was knocked down by shRNA 
transfection. 
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Figure 5.1. 2  a schematic representation of the PI3K/Akt/mTOR pathway.  
(Adapted from Vara et al, 2004)  
 
 
 
 
 
 
 
 
 
110 
 
5.2 Results 
5.2.1 Stable knockdown of T21 using short hairpin RNA (shRNA): 
 
In order to study the effect of long term (stable) silencing of T21 on cellular proteins and 
their activity, short hairpin RNA (shRNA) for stable transfection was used. As shown in the 
previous chapter, T21 siRNA3 caused a significant knockdown of T21 in PC3 prostate cancer 
cells, therefore shRNA was customized to include this sequence; the pGFP-B-RS mammalian 
expression vector containing the T21-specific sequence (purchased from Origene 
Technologies) along with a scramble cassette control vector (Figure 5.2.1.1) were 
constructed. PC3 cells were transfected with either T21-shRNA or control vector as described 
in Chapter 2. 
 
T21 unique region shRNA - Top strand sequence (5’ – 3’) (sense, loop and 
antisense)  
5'-GCACAGGAATTCTTGATCA TCAAGAG 
TGATCAAGAATTCCTGTGC-3'  
 
Figure 5.2.1. 1 pGFP-B-RS mammalian expression vector (Origene Technologies). 
 Vector contains a Blastacidin resistance gene used to select following cell transfection as 
well as GFP reporter gene. A non-effective 29mer scrambled shRNA cassette in pGFP-B-RS 
vector was also purchased from Origene Technologies as a negative control. 
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On the following day of the transfection, the majority of PC3 cells expressed GFP (Green 
Fluorescence Protein) (Figure 5.2.1.2). Then, the transfected cells were grown in media 
supplemented with Blasticidin (selective antibiotic) over one passage before single colonies 
were achieved through limiting dilution assays. Although T21 protein expression was indeed 
decreased after shRNA transfection, the effects of the silencing were short-lived and T21 
expression returned to that of the control cells after a number of passages (data not shown). 
Therefore, further refinement of the transfection methodology was undertaken, including the 
antibiotic concentration used, timing of fresh antibiotic supplements to the media and further 
cell sorting using flow cytometry and FACS sorting in an attempt to establish a more stably 
transfected cell line. In brief, following culture of clones positively expressing GFP, the 
expanded colonies that demonstrated the most stable significant knockdown compared to 
control cells were sorted for GFP positive expressing cells using a MoFlo XDP High-Speed 
Cell Sorter (Beckman Coulter) (method descripted in Chapter 2). The obtained clones were 
returned to culture. Once the cells were sufficient in number, mRNA was extracted and 
reverse transcribed to synthesise cDNA in order to assess for the expression of T21 using 
qRT-PCR. Further sorted clones were cultured to be used for investigating protein expression 
using immunoblotting technique. 
 
                                            T21-shRNA                        Control shRNA 
  
Figure 5.2.1. 2 Immunofluorescence images demonstrating GFP (Green Fluorescence 
Protein) expression in PC3 cells. 
 Immunofluorescence images of PC3 cells showing GFP expression one day following T21 
specific shRNA transfection. 
 
Following shRNA transfection, clones were selected for further sorting of GFP-positive cells 
and qRT-PCR was performed. The analysis of qRT-PCR showed a significant T21 
knockdown following transfection of the PC3 cell line with pGFP-B-RS vector containing 
T21 shRNA (Figure 5.2.1.3). 
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Figure 5.2.1. 3  qRT-PCR of T21 stable knockdown of the PC3 prostate cancer cell line 
following T21 specific shRNA transfection. 
 Experiments were carried out three times in triplicate (n=3). The results are given as the 
standard error of mean with relative expression of T21 shRNA in PC3 to the control shRNA. 
 
In addition, T21 protein expression in PC3 cells lysates by western blotting following T21 
specific shRNA transfection demonstrated a significant decrease compared to control 
shRNA. The protein expression in PC3 lysate treated with T21 shRNA showed no band 
detectable at approximately 57kDa, whereas this band was apparent in control shRNA treated 
cells (Figure 5.2.1.4). 
These results confirmed the silencing of T21 protein expression following T21 shRNA 
silencing and these samples were subsequently used to investigate changes in protein kinase 
activity using proteome profiler arrays.  
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Figure 5.2.1. 4 Western blot analysis of T21 protein expression following T21 specific 
shRNA transfection. 
 Protein expression following culture of PC3 clones post T21-shRNA transfection compared 
to control cells. Above: T21 identified (57 kDa band). Below: β-actin (45 kDa Band), 
representative protein loading control (n=2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ladder 
T21- 
shRNA 
57 kDa 
45 kDa 
Control 
shRNA 
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5.2.2 The effect of stable T21 knockdown on MAPK proteome profiler 
   
MAPK proteome arrays (R & D Systems) specific for the MAPK and PI3K pathways were 
used to determine the effect of T21 knockdown on their phosphorylation status. Therefore, 
the relative levels of phosphorylated forms of specific signaling proteins involved in these 
pathway cascades were investigated. Protein lysates were extracted from the T21 and control 
PC3 cells treated with shRNAs, diluted and mixed with a cocktail of biotinylated detection 
antibodies. The samples were then incubated with nitrocellulose membranes spotted in 
duplicate with antibodies against different kinases and their substrates (Table 5.2.2.1). 
Streptavidin-Horseradish Peroxidase and chemiluminescent detection reagents were added 
for signal detection. Representative images of the arrays are shown in Figure 5.2.2.2. Every 
two spots seen in the image represents a duplicate of phosphorylation status corresponding to 
kinases or kinase substrates. Both the positive and negative controls for each array are 
highlighted.in green and red respectively 
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(A) 
Akt1 HSP27 p38 β 
Akt2 JNK1 p38 δ 
Akt3 JNK2 p38 ϒ 
Akt pan JNK3 p53 
CREB JNK pan p70 S6Kinase 
ERK1 MKK3 RSK1 
ERK2 MKK6 RSK2 
GSK-3 α/β MSK2 TOR 
GSK-3 β p38 α 
 
(B) 
 
 
Table 5.2.2. 1 List of 26 antibodies included sequentially in the Human Phospho-MAPK 
Array. 
 (A) List of the antibodies. (B) Human Phospho-MAPK Proteome Profiler array coordinates 
in duplicate to detect the relative phosphorylation of these kinases in a single sample. 
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The data from the MAPK array showed various reductions in the duplicated spots of kinases 
and their substrate protein expressions. p38α and CREB in particular showed a recognised  
protein expression reduction in PC3 cells after T21 knocked down with shRNA. Moreover, 
RSK1 and RSK2 were reduced in their protein expression with T21 silencing compared to 
control shRNA treated cells. Further slight reductions were observed for Akt2, Akt pan, 
ERK1, MKK3 and GSK-3β upon T21 silencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
117 
 
 
Control shRNA 
 
T21 shRNA 
 
 
Figure 5.2.2. 1 Human Phospho-MAPK Proteome Profiler array images.  
Protein expression obtained from Control shRNA and T21 shRNA cells lysates (n=2). 
Duplicate spots represent the capture region for a specific signaling protein and its repeat. 
Positive controls are highlighted in green (Reference spots) and negative controls in red 
(PBS). 
 
The images were subjected to densitometry analysis to obtain accurate levels of protein 
phosphophorylation. The average of these readings is shown in Figure 5.2.2.2. As highlighted 
here, there appeared to be a difference in the levels of certain phospho-proteins known to be 
tumour associated. In particular, it showed that when T21 protein was reduced, there was a 
decrease in the levels of both Akt2 and GSK-3β proteins, both of which are involved in the 
PI3K signaling pathway. In comparison to ERK-1, there was no noticeable drop in the level 
of expression of phosphorylated ERK-2 under these conditions. For the former two proteins, 
this would suggest that when T21 is expressed by tumours, then there would be an increase in 
 
 
Reference 
spots 
Reference 
spots 
Reference 
spots 
PBS 
p38α 
Akt2 Akt pan CREB ERK1 GSK-3β 
MKK3 
RSK1 RSK2 
 
 
 
Reference 
spots 
Reference 
spots 
Reference 
spots 
PBS 
p38α 
Akt2 Akt pan CREB ERK1 GSK-3β 
MKK3 
RSK1 RSK2 
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the level of their phosphorylated form, suggesting possible post-translational modification 
resulting from T21 knockdown expression. 
 
 
Figure 5.2.2. 2 Densitometry readings of the images from the Phospho-MAPK Arrays 
shown in Figure 5.2.2.1.  
Duplicate spots represent the capture region for a specific signaling protein and its repeat 
versus positive controls (n=2).  
 
As a result, there appeared to be a difference in the levels of certain phospho-proteins, as a 
consequence of T21 silencing. Specifically, it seemed that when T21 was decreased, there 
were decreases in the levels of Akt2, CREB, GSK-3β and RSK1 when using stable 
knockdown. In addition MSK2, ERK2 levels were decreased following transient T21 
knockdown using siRNA. Conversely, it was noted that there was a slight in increase in the 
levels of Akt3, JNK2 and JNK3 when T21 shRNA were used and only PSK1 was slight 
increases as a result of transient knockdown under the same conditions (data of T21 siRNA 
knockdown on MAPK proteome profiler not shown). 
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5.3 Discussion: 
 
As described at the beginning of the previous chapter, T21 siRNA 3 silenced T21 expression 
at the mRNA level in PC3 to a significant degree at 48 hours. Therefore, it was crucial to 
assess the ability of this assay whether T21 shRNA transfection could achieve silencing and 
also decrease T21 protein expression. shRNA was therefore customised using the pGFP-B-
RS mammalian expression vector containing the T21-specific sequence (purchased from 
Origene Technologies) along with a scramble cassette control vector as (described in 
methodology section of chapter 2). PC3 cells were then treated with T21 shRNA and control 
shRNA and T21 expression levels confirmed by qRT-PCR technique to demonstrate T21 
knockdown at the gene expression level. Subsequently, once T21 protein knocked down had 
been achieved, further analysis of the phosphorylation status of proteins associated with the 
MAPK pathway and its substrates was undertaken.  
PC3 cells treated with T21 shRNA and control shRNA were lysed and western bolting was 
carried out. The protein expression of T21 showed successful silencing of a band at 
approximately 57kDa compared to the control shRNA, which was the molecular mass 
corresponding to the previously determined size of T21 previously obtained in chapter 3 
using western bolting. As T21 was silenced and confirmed at the protein expression level, the 
lysed PC3 cells treated with T21 and control shRNA were applied to a MAPK proteome 
phospho-protein profiler array. These experiments were performed to determine the effect of 
T21 expression / knockdown on various proteins involved in cancer development and 
progression. The MAPK proteome profiler array was chosen because of the importance of 
these pathways in cancer and to confirm the results of NGS data analysis in chapter 4.  
Both NGS and MAPK proteome profiler array data obtained in the present study and 
knowledge of their corresponding pathways has given new insight to our understanding the 
role of T21 in cancer. For instance, from the MAPK array data, increased phosphorylation of 
the PI3K effectors Akt and GSK-3 is links to enhanced cell proliferation. It was also shown 
that the impact of T21 expression on proteins involved in cell cycle progression, such as 
MAPK6 and FGF1, were validated by the NGS data. Collectively this infers that T21 
represents a pivotal control over pathways that are intimately involved in cancer cell survival 
and growth, as demonstrated here by altered expression of members of the MAPK pathway. 
120 
 
MAPK array images demonstrated differing protein expression patterns for MAPK kinases. 
P38 α and CREB showed a significant lower protein expression following T21 knocked down 
compared to control shRNA. p38 MAPKs (α, β, γ, and δ) are members of the MAPK family 
which are activated  due to a variety of environmental stresses and the presence of 
inflammatory cytokines. In MAPK cascades, the membrane-proximal component is a 
MAPKKK, typically a MEKK or a mixed lineage kinase (MLK). The MAPKKK 
phosphorylates and activates MKK3/6 and p38 MAPK kinase. MKK3/6 can also be activated 
directly by ASK1, which is stimulated by apoptotic stimuli. p38 MAPK is involved in 
regulation of HSP27, MAPKAPK-2 (MK2), MAPKAPK-3 (MK3), and several transcription 
factors including ATF-2, Stat1, the Max/ Myc complex, MEF-2, Elk-1, and indirectly CREB 
via activation of MSK1 (Figure 5.3.1) (Plotnikov et al., 2011;  Huang etal., 2010; Cargnello 
and Roux, 2011). 
In addition, CREB has a role in activating the transcription of target genes in response to a 
wide range of stimuli, including neurotransmitters, hormones, growth factors, synaptic 
activity, stressors and inflammatory cytokines. These stimuli activate a variety of intracellular 
signaling pathways, leading to activation of a number of protein kinases such as PKA, 
Ca2+/CaMKIV, and MAPK (figure 5.3.2) (Tardito et al., 2006). 
These complex molecular networks operate to determine cell behaviour and to the best of my 
knowledge this is the first time that T21 has been ascribed a definitive role in cancer cell 
growth regulation. Thus, the application of gene silencing techniques has allowed its potential 
role in cancer to be better defined and suggests that T21 is potentially a main player in the 
cancer process. 
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Figure 5.3. 1 The MAP kinase signaling cascades during phosphorylation of MAPKKK 
to MAPKK to MAPK.  
 
In 2014, Barrantes and Nebreda reviewed recent progress in understanding how the p38 
MAPK signalling pathway participates in the different steps of metastasis in order to 
understand the roles of p38 MAPKs in invasion and metastasis suggesting that tumour cells 
need to modulate p38 MAPK activity levels to successfully metastasise (Barrantes and 
Nebreda, 2014). 
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Figure 5.3. 2 Schematic representation of the signaling pathways modulating CREB 
activation. 
(adapted from De Cesare et al. (1999) 
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6 CHAPTER SIX: General Discussion 
 
6.1 Introduction and rationale for the study 
 
T21 was identified as a prostate-associated tumour antigen using a modified SEREX 
expression cloning method and has been shown to elicit a humoral immune response in 
prostate cancer patients. It has also been shown to be over-expressed in malignant glands of 
prostate cancer compared to benign glands and stroma at the mRNA level. In addition, T21 
expression has been associated with tumour stage and correlated with increasing Gleason 
grade and PSA recurrence (Miles et al. 2007, Miles et al. 2012). Previous studies suggested 
that T21 was a prostate cancer antigen of potential immunotherapeutic importance and 
therefore worth further characterisation and investigation. As T21 fundamentally shares 
remarkable similarity with the Centrosomal Protein CEP290, which has been implicated in 
several cilia related syndromic disorders such as Joubert syndrome, it was considered 
imperative to determine the differences and similarities between these two molecules and to 
facilitate further studies on the role of T21 in prostate cancer progression, especially at the 
molecular level. 
The precise molecular function of this novel molecule (T21) in cancer was unknown and this 
constituted the basis of my thesis. The study focused on elucidating the role of T21 in the 
regulation of cellular pathways involved in prostate cancer. Following successful knockdown 
(silencing) of T21 mRNA and protein, gene expression profiling, by Next Generation 
Sequencing (NGS), made it possible to analyse the genome of human prostate cancer cells 
treated with interfering RNA. Genes that were either up or down regulated in the presence of 
T21 provided evidence that T21 may share functional activity and interact with these various 
genes. 
To further investigate the role of T21 in the regulation of cellular pathways during prostate 
tumourigenesis, a proteome profiling approach was performed to investigate MAPKinase 
pathways. The mitogen activated protein kinase (MAPK) signaling network represents 
another cascade that are significantly modified in tumour cells. There are several MAPK 
pathways that are involved in a series of cell processes including proliferation, differentiation, 
apoptosis, migration and cell transformation.  They consist of different pathways that interact 
with one another to bring about their action. What is clear from the results of this present 
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study is that T21 does indeed affect the expression of a wide variety of genes, including many 
associated with MAPK signaling and is therefore likely to play a central role in the cancer 
process. 
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6.2 T21 and CEP290 mRNAs and protein expression in cancer cell lines: 
 
The recognition that the centrosomal protein CEP290 has a significant degree of homology to 
T21 has raised important questions with regards to its molecular and protein expression in 
prostate cancer cells. In order to address these questions, CEP290 was assessed alongside 
T21 to understand the relationship between the two molecules at their molecular level, 
including protein expression. The qRT-PCR data specific for CEP290 and T21 showed 
different expression profiles using newly designed, specific primers. Furthermore, CEP290 
silencing was performed to investigate its effect on T21 expression which was assessed using 
qRT-PCR and to determine the relationship between CEP290 and T21. This approach led to 
the investigation of CEP290 knockdown on prostate cancer cell proliferation. 
Various cancer cell lines (including prostate cancer cell lines) were screened using CEP290 
and T21 specifically designed primers. The results illustrated different molecular 
characteristic between them. CEP290 and T21 are two different products that are expressed 
differently at the mRNA level. The successful development of RNA interference techniques 
meant that functional assays on prostate cell lines could be performed. The assessment of 
CEP290 knockdown and its effect on T21 in prostate cancer using siRNA revealed 
interesting data. CEP290 knockdown using specific siRNAs showed no significant effects on 
T21 expression (qRT-PCR data in chapter 3). This approach was also used to assess the 
impact of CEP290 transient knockdown on cell proliferation. Following CEP290 silencing in 
PC3 and DU145, apoptotic cells were observed over time (24, 48 and 72 hours) in culture 
(data not shown) and proliferation of 
3
H thymidine incorporation seems to be slightly reduced 
in PC3 cells upon CEP290 silencing, compared to the siRNA controls. 
The results obtained above were further confirmed using a T21 antibody which recognizes 
specifically the unique (exon) region of T21. By immunoblotting, this antibody recognised a 
unique band of approximately 55kDa when using LNCaP cell lysates and a band at 57kDa in 
PC3 and DU145 lysates. This difference in the molecular weights is most likely due to post-
translational modifications that tend to positively charge the protein hence a difference in the 
protein molecular weight (e.g. Phosphorylation, sumoylation).  Interestingly, immunoblotting 
with CEP290 antibody using these cell extracts showed a different expression pattern which 
confirmed that T21 is a separate protein product from CEP290 protein. This was one of the 
main aims of the study and so gave credence to further investigations on the function of T21. 
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Taken together, the mRNA and protein expression data shown here, depicts T21 as a different 
product from CEP290 and strongly argues the case for T21 involvement in promoting tumour 
proliferation. Other published evidence has provided preliminary data showing that T21 and 
CEP290 are differentially expressed, suggesting that the T21 unique region antibody 
compared to the CEP290 cross –reacting antibody can distinguish between the two proteins 
(Miles et al. 2012). Alternative splicing is a common post transcriptional process that can be 
used to generate multiple transcript variants from a single gene and can play an important 
role in cellular development, differentiation and neoplasia (Black, 2003). Thus, this is the 
likely explanation for the transcription of members of the CEP290 family of variant proteins, 
including T21. This aspect of study has enhanced our understanding of the expression and 
role of T21 in prostate cancer cell lines. T21 may therefore be considered as a target of 
interest that would be considered as a useful biomarker for immunotherapeutic applications 
when increased T21 protein may be detectable in serum or urine from prostate cancer patients 
(Miles et al., 2012). This has not been investigated and represents an obvious avenue for 
further study, using for example highly sensitive ESI TOF-TOF mass spectrometry to 
confirm the presence of T21 in as a secreted product in blood or urine. 
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6.3 Investigating the role of T21 in prostate cancer tumourigenesis: 
 
Having confirmed that T21 is differently expressed at the RNA and protein level in prostate 
cancer cell lines, the next logical question was to attempt to address the functional 
significance of T21 in tumourigenesis. With regards to characterising antigens as potential 
markers or therapeutic targets, it was clear that T21 had promise and studies were therefore 
initiated to investigate its function using siRNA and shRNA silencing techniques. T21 siRNA 
3 showed a significant ability to silence T21 in PC3 cells, as confirmed by qRT-PCR data 
analysis 48 hours following the transfection. Moreover, cellular proliferation, assayed using 
3
H Thymidine incorporation, showed a reduction in cell proliferation after 48 and 72 hours 
following T21-siRNA silencing. This suggests a potential role for T21 in cancer proliferation. 
Therefore, two different approaches were utilised in order to understand more precisely the 
role of T21 in cancer cell signaling pathways: Next Generation Sequencing (NGS) and 
Proteome profiler arrays.  
Next Generation Sequencing (NGS) data had been previously obtained as a result of T21 
knockdown in PC3 cells. These data indicated that T21 functions by regulating several 
cellular pathways involved in tumourigenesis. The expression of a number of genes was 
affected by T21 silencing; specifically, T21 siRNA knock down significantly up regulated 
(197 genes) or down regulated (26 genes). Following a more focused examination of gene 
function and literature searching, a more refined shortlist of 20 genes that had roles in the 
processes involved in cancer were chosen to illustrate and confirm the general changes in 
mRNA expression and to extrapolate potential functional attributes of T21 and the role they 
might play in the cancer progression. 
The data obtained from NGS following T21 knockdown experiment in PC3 prostate cancer 
cells was used for bioinformatics modelling of cellular pathway(s) that were altered following 
knockdown of T21. Several genes were categorised as up-regulated and down-regulated and 
were selected based on a significant fold change in expression. These genes were classified 
into different groups corresponding to their function within the cell (involvement in cell 
proliferation, apoptosis, cell adhesion, cell cycle and cell proliferation). The selection of a 
panel of genes to be included for further studies was based on a minimal 2 fold-change when 
compared to their expression in the control group. This selection also relied on published 
literature in the field of cancer where those genes were reported to be altered in cancer cells. 
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Functions of genes undergoing significant changes of expression were obtained using a 
variety of web tools such as OMIM or GeneCards. Subsequently, a list of up regulated and 
down regulated genes were selected according to their potential pathways and the NGS data 
was validated by using qRT-PCR and specific primers. Primers for up and down regulated 
genes were obtained and optimised, then, qRT-PCR was performed using PC3 prostate 
cancer cell mRNA generated under optimal conditions: treating with siRNA (T21 vs control) 
as a transient knockdown after 48 hours. The qRT-PCR results confirmed and validated the 
results obtained by NGS for selected up and down regulated genes, providing further 
evidence that T21 may not only share common protein functions with them, but also that T21 
is a central player in regulating the expression of these genes. 
 The data indicated the up regulation of genes were involved, for instance, in the promotion 
of tumourigenesis through cell proliferation and cell cycle control such as MAPK6 (Hoeflich 
et al., 2006). Overriding DNA damage pathways and promoting cell survival, for example, 
through the tumor suppressor homeodomain-interacting protein kinase-2 (HIPK2) which is 
essentially a nuclear protein and is involved prominently within two fundamental cellular 
functions involving cell cycle/apoptosis regulation and transcription steering, is of 
significance and appears to involve, at least in part, the activity of T21 (Kondo et al., 2003; 
Wiggins et al., 2004). HIPK2 has also has been identified as an interacting protein with p53, 
that is phosphorylated by HIPK2 at Ser46 leading to activation of pro-apoptotic target genes 
(D’Orazi et al., 2002; Hofmann et al., 2002).  
The up regulation of genes such as CALM3 may be indicative of a more specific role for T21 
in centrosomal and structural rearrangement during mitosis. CALM3 has been previously 
detected within significant under-expression of genes in colorectal cancer, providing further 
evidence of its implicating in cancer development at this site (Mlakar et al., 2009). Moreover, 
genes that were suppressed play regulatory roles during tumour progression, through 
regulation of RAS family members (RAB6B, FRS3) or those genes that involved in MAPK 
and Akt pathways (Tomasovic et al, 2012). Cell stress/DNA repair pathways in the 
chromodomain helicase DNA-binding family member CHD8 can bind to p53 and suppress its 
transactivation activity by recruiting histone H1 during embryogenesis and has been shown to 
play a key role as a tumor suppressor in gastric cancer (Nishiyama et al. 2009; Sawada et al., 
2013).  
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Therefore, the results from NGS data validation indicated an up regulation of some genes that 
promote tumourigenesis through various molecular networks, including cell proliferation and 
survival, centrosome and structural rearrangement and cell cycle control in addition to the up 
regulation of those genes that would inhibit the response to DNA damage and those that 
modulate immune responses. In contrast, genes involved in regulatory pathways were 
suppressed in the presence of T21 and included RAS family members, cell stress/DNA repair 
pathways and the PI3K-Akt pathway. Although a full and through analysis is essential to 
fully elucidate pathways that may involve T21 activity, the data presented here indicate that 
T21 appears to be involved in promoting tumourigenesis and therefore could represent an 
attractive target for therapy. 
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6.4 T21 role in Cell Signalling Pathways and Cancer: 
 
Further knockdown experiments were performed using T21 specific shRNA transfection, 
which were used successfully to study what long term effects arise from silencing of T21 
expression. Although the selected NGS data was successfully validated using qRT-PCR, 
further investigations at the protein level were performed in order to analyse potential 
signaling pathways and the effects of T21 knockdown in PC3 prostate cancer cells. 
Therefore, proteome profiler arrays were used for studying the protein expression and 
subsequently to analyse the interactions of T21 and their role in cancer progression. MAPK 
Proteome Profiler arrays were used in order to assess the effect of T21 knockdown on their 
phosphorylation status. Cells transfected in this manner represented the ideal way of further 
investigating T21. 
Akt is a primary mediator of PI3K-initiated signaling and has a number of effective 
downstream substrates such as cAMP-response-element-binding protein (CREB) signaling 
which has been reported to be associated with malignant transformation (Son et al, 2010). 
The activation of CREB due to Akt phosphorylation leads to inactivation of glycogen 
synthase kinase-3 (GSK-3) that has a role in promoting cell survival and cell cycle 
progression (Nicholson and Anderson, 2001). T21 silencing by shRNA showed a noticeable, 
significant reduction in the expression of CREB compared to the control shRNA. 
p38α MAPK, on the other hand, showed lower expression as a result of T21 knockdown and 
it has been approved previously that p38 MAPK signaling may be involved in various steps 
in metastasis and has a potential role in cancer invasion (Barrantes and Nebreda, 2014). The 
previous published findings suggested that p38α MAPK function may contribute to cell cycle 
defects and tumorigenesis. Also, p38α role was observed to induce terminal differentiation 
and inhibit the proliferation of rhabdomyosarcoma-derived cells which is one of the most 
common solid tumors of childhood, occurring as a consequence of defects in the 
differentiation of muscle precursor cells, which was attributed to deficiency in p38 MAPK 
activity (Puri et al., 2000). These potential pathways were altered as a result of T21 silencing 
as shown by NGS data analysis and proteome MAPK array data. This suggests a line of 
investigation that would allow us to further understand the actual role of T21 and verify its 
possible function as a tumour antigen.  
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6.5 Conclusion and Future Work 
 
Immunotherapy provides a real promise for developing new therapies to target cancer and the 
identification of Tumour Associated Antigens (TAAs) is crucial in developing these targeted 
therapies. TAAs expression patterns are predominantly confined to tumours and healthy testis 
and placenta and would be re-expressed during cancer transformation to carry out specific 
roles in malignant cells. T21 as a tumour antigen and as a potential immunotherapeutic was 
identified by a modified SEREX technique and classified as Cancer-Testis Antigens (CTAs). 
Represents a promising means to be used as a potential immunotherapeutic target. Very little 
information is available about the role of CTAs in cancer cells. The present study was 
undertaken to increase our knowledge on T21 in cancer and more specifically in order to 
assess and understand its role in cancer development and progression. 
 
From the data presented here, the evidence suggests that T21 is in fact a transcript variant of 
the centrosomal gene CEP290. T21 mRNA and protein was shown to be differentially 
expressed using designed primers targeting the T21 “unique region” sequence when 
compared to CEP290. Data collected also using immunofluorescence indicated that T21 was 
not localised to the centrosome, suggesting further that T21 activity is independent of that of 
CEP290. Although assessment of cell proliferation following T21 gene knockdown 
demonstrated an association between T21 and increased tumour cell proliferation, further 
investigations were required to determine the potential pathways that are associated with this 
process. T21 gene silencing studies have shown the possible involvement of this antigen in 
processes disrupted in cancer, in addition to its positive influence in cell proliferation.  
 
The analysis and experimental verification of the NGS data by qRT-PCR described here 
strongly suggested a role for T21 in cell proliferation and survival, modulation of immune 
responses and suppression of regulatory processes involved in tumourigenesis. As a result, 
data collected and validated at this stage provided an argument to implicate T21 in a wider 
context and other aspects of malignant cell biology. 
 
Further investigations were performed following T21 stable knockdown using shRNA and 
the use of proteome profiler arrays. The data obtained by use of a MAPK proteome profiler 
array showed various effects of T21 silencing on some MAPK proteins especially on p38α as 
well as CREB.  
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In summary, this study set out to characterise a SEREX-defined antigen T21 in order to 
ascertain its value as a diagnostic/prognositic marker through molecular expression analysis 
and functional studies and to further understand its role in the cancer process. A final 
objective was to determine its candidacy as a potential target for immunotherapy. The results 
presented here indicated that T21 is a CT antigen functionally involved in key signaling 
pathways important in cancer. Further studies should address in more detail the implications 
of these findings in the molecular signaling events that maintain and progress the malignant 
phenotype. Effective technology such as Genechip oligonucleotide microarray and mass 
spectrophotometry platforms could be used appropriately to confirm T21 as a target 
biomarker in accessible samples like blood and urine. Further confirmatory analysis of the 
MAPK and other pathways are suggested from the results obtained here and here is still the 
need to address the potential of T21 as an immune target for vaccine therapy. From the 
defined protein structure and given the identification of the unique (exon) stretch of amino 
acids, studies should be undertaken to define MHC restricted epitopes within this region and 
assess their ability to potentiate T cell mediated immunity together with the natural 
expression of immunogenic peptides associated with cell surface expressed MHC class I 
antigen.       
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